[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 817
1. Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Ilic M, Stokić E: Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron. Intern Med; 2007;46(13):945-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron.
  • OBJECTIVE: Insulin resistance and metabolic syndrome (MeS) are common in end-stage renal disease (ESRD) patients on maintenance hemodialysis (HD).
  • Such metabolic and clinical abnormalities may lead to an increased risk for cardiovascular disease.
  • Logistical regression analysis was used to evaluate the correlation between measured variables and the presence of MeS in HD patients.
  • CONCLUSION: The present study demonstrated that serum iron participated together with independent predictors, glucose and BMI, in the pathogenesis of IR and MeS of ESRD patients on maintenance HD.
  • [MeSH-minor] Adult. Analysis of Variance. Blood Glucose / analysis. Body Composition. Body Mass Index. Cardiovascular Diseases / prevention & control. Case-Control Studies. Cohort Studies. Female. Follow-Up Studies. Humans. Incidence. Inflammation / diagnosis. Inflammation / epidemiology. Logistic Models. Male. Middle Aged. Nutritional Status. Predictive Value of Tests. Risk Factors. Severity of Illness Index. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603231.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Blood Glucose; 9007-41-4 / C-Reactive Protein; 9007-73-2 / Ferritins
  •  go-up   go-down


2. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC, TRACK-HD investigators: Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol; 2009 Sep;8(9):791-801
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
  • BACKGROUND: Huntington's disease (HD) is an autosomal dominant, fully penetrant, neurodegenerative disease that most commonly affects adults in mid-life.
  • Our aim was to identify sensitive and reliable biomarkers in premanifest carriers of mutated HTT and in individuals with early HD that could provide essential methodology for the assessment of therapeutic interventions.
  • Blinded analyses were done on the baseline cross-sectional data from 366 individuals: 123 controls, 120 premanifest (pre-HD) individuals, and 123 patients with early HD.
  • Cross-sectional analyses identified significant changes in whole-brain volume, regional grey and white matter differences, impairment in a range of voluntary neurophysiological motor, and oculomotor tasks, and cognitive and neuropsychiatric dysfunction in premanifest HD gene carriers with normal motor scores through to early clinical stage 2 disease.
  • Many parameters differ from age-matched controls in a graded fashion and show changes of increasing magnitude across our cohort, who range from about 16 years from predicted disease diagnosis to early HD.
  • [MeSH-major] Biomarkers / analysis. Brain / physiopathology. Huntington Disease / diagnosis. Huntington Disease / physiopathology
  • [MeSH-minor] Adolescent. Adult. Aged. Atrophy / diagnosis. Atrophy / pathology. Atrophy / physiopathology. Cognition Disorders / diagnosis. Cognition Disorders / etiology. Cognition Disorders / physiopathology. Cohort Studies. Cross-Sectional Studies. Disease Progression. Early Diagnosis. Female. Genetic Predisposition to Disease / genetics. Genetic Testing. Heterozygote Detection / methods. Humans. Longitudinal Studies. Magnetic Resonance Imaging. Male. Middle Aged. Neurologic Examination / methods. Predictive Value of Tests. Reference Values. Young Adult

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mov Disord. 2008 Jun 15;23(8):1100-7 [18412252.001]
  • [Cites] Neurology. 2004 Jul 13;63(1):66-72 [15249612.001]
  • [Cites] Prog Brain Res. 2008;171:555-8 [18718352.001]
  • [Cites] Mov Disord. 2009 Apr 30;24(6):932-6 [19243073.001]
  • [Cites] Comput Med Imaging Graph. 2002 Jul-Aug;26(4):251-64 [12074920.001]
  • [Cites] Neurology. 2000 Jan 25;54(2):452-8 [10668713.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):544-9 [10676962.001]
  • [Cites] Clin Genet. 2004 Apr;65(4):267-77 [15025718.001]
  • [Cites] Nat Rev Neurosci. 2004 Mar;5(3):218-28 [14976521.001]
  • [Cites] Neurology. 1979 Jan;29(1):1-3 [154626.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):387-92 [8401587.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] Ann Neurol. 1996 Jul;40(1):49-54 [8687191.001]
  • [Cites] Comput Methods Programs Biomed. 1997 May;53(1):15-25 [9113464.001]
  • [Cites] Ann Neurol. 1997 May;41(5):689-92 [9153534.001]
  • [Cites] Neurology. 1999 Sep 11;53(4):806-12 [10489045.001]
  • [Cites] Neurology. 2005 Sep 13;65(5):745-7 [16157910.001]
  • [Cites] Biol Psychiatry. 2006 Jan 1;59(1):57-63 [16112655.001]
  • [Cites] J Nucl Med. 2006 Feb;47(2):215-22 [16455626.001]
  • [Cites] Arch Neurol. 2006 Jun;63(6):883-90 [16769871.001]
  • [Cites] Neurology. 2006 Aug 8;67(3):485-7 [16625001.001]
  • [Cites] Brain. 2007 Jul;130(Pt 7):1732-44 [17584778.001]
  • [Cites] J Int Neuropsychol Soc. 2007 Sep;13(5):758-69 [17697407.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2007 Sep;78(9):939-43 [17178819.001]
  • [Cites] Brain. 2007 Nov;130(Pt 11):2845-57 [17855375.001]
  • [Cites] Brain. 2008 Jan;131(Pt 1):196-204 [18056161.001]
  • [Cites] Neuropsychologia. 2008;46(8):2152-60 [18407301.001]
  • [Cites] Cell. 2000 Mar 31;101(1):57-66 [10778856.001]
  • [Cites] Exp Neurol. 2000 May;163(1):136-48 [10785452.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Dec;69(6):773-9 [11080230.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Jan;20(1):70-80 [11293693.001]
  • [Cites] Neuropsychiatry Neuropsychol Behav Neurol. 2001 Oct-Dec;14(4):219-26 [11725215.001]
  • [Cites] Neurology. 2002 Mar 12;58(5):695-701 [11889230.001]
  • [Cites] Acta Psychiatr Scand. 2002 Mar;105(3):224-30 [11939977.001]
  • [Cites] Brain. 2002 Aug;125(Pt 8):1815-28 [12135972.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):874-80 [18096682.001]
  • (PMID = 19646924.001).
  • [ISSN] 1474-4422
  • [Journal-full-title] The Lancet. Neurology
  • [ISO-abbreviation] Lancet Neurol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS042861-04; United States / NINDS NIH HHS / NS / P01 NS058793; United States / NCRR NIH HHS / RR / M01 RR001066-305062; United States / NINDS NIH HHS / NS / R01 NS042861; United States / NINDS NIH HHS / NS / P01 NS058793-02; United States / NCRR NIH HHS / RR / M01 RR001066; United States / NINDS NIH HHS / NS / P01 NS058793-01A10001; United Kingdom / Medical Research Council / / G0601846; United States / NINDS NIH HHS / NS / R01 NS042861-05
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS173425; NLM/ PMC3725974
  • [Investigator] Coleman A; Dar Santos R; Decolongon J; Sturrock A; Bardinet E; Jauffret C; Justo D; Lehericy S; Marelli C; Nigaud K; Valabrègue R; Bechtel N; Hoffman A; Kraus P; van den Bogaard SJ; Dumas EM; van der Grond J; t'Hart EP; Jurgens C; Witjes-Ane MN; Arran N; Frost C; Jones R; Hobbs N; Lahiri N; Ordidge R; Owen G; Pepple T; Read J; Say M; Wild E; Keenan S; Cash DM; Axelson E; Wang C; Lee S; Monaco W; Campbell C; Queller S; Whitlock K; Campbell C; Campbell M; Frajman E; Michman C; O'Regan A
  •  go-up   go-down


3. Powell S, Dudek AZ: Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res; 2009 Oct;29(10):4189-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
  • BACKGROUND: High-dose interleukin-2 (HD IL-2) is known to produce durable responses in metastatic melanoma.
  • The purpose of this study was to evaluate the response of metastatic melanoma to treatment with HD IL-2.
  • PATIENTS AND METHODS: A retrospective analysis was performed on all adult patients with stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at the University of Minnesota.
  • HD IL-2 was given intravenously every 8 hours at 600,000 IU/kg for a maximum of 14 doses per course.
  • RESULTS: Fifteen patients with metastatic melanoma had been treated with HD IL-2.
  • There were 4 patients exhibiting some response, with 1 complete response (CR), 1 partial response (PR), 1 mixed response (MR) and 2 stable disease (SD).
  • Average time to disease progression (TTDP) was 5.67 months.
  • Two patients had complete resolution of brain lesions after HD IL-2 therapy.
  • One of these patients experienced CR and is disease free 34 months after stopping therapy.
  • The other patient experienced MR and is currently alive with disease, but without recurrence of brain lesions.
  • CONCLUSION: We propose further evaluation of HD IL-2 in patients with brain metastases because this patient population is typically considered ineligible for HD IL-2 therapy.
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Female. Humans. L-Lactate Dehydrogenase / metabolism. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846971.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interleukin-2; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


Advertisement
4. Yamasaki H, Sandrof MA, Boekelheide K: Suppression of radiation-induced testicular germ cell apoptosis by 2,5-hexanedione pretreatment. I. Histopathological analysis reveals stage dependence of attenuated apoptosis. Toxicol Sci; 2010 Oct;117(2):449-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of radiation-induced testicular germ cell apoptosis by 2,5-hexanedione pretreatment. I. Histopathological analysis reveals stage dependence of attenuated apoptosis.
  • 2,5-Hexanedione (HD) and x-radiation (x-ray) are testicular toxicants, each with a unique cellular target.
  • HD exposure disrupts microtubule function in Sertoli cells, and x-ray exposure causes double-strand breaks in the DNA of germ cells.
  • In this study, adult male F344 rats were exposed to 1% HD in the drinking water for 18 days with or without coexposure to 2 or 5 Gy x-ray 12 h prior to necropsy.
  • Incidence of retained spermatid heads was increased in the HD and coexposure groups.
  • There was a striking stage-dependent attenuation of apoptosis with coexposure compared with x-ray alone.
  • Detailed histopathological analysis revealed a significant suppression of x-ray-induced germ cell apoptosis by HD pretreatment in stages I-VI of the seminiferous cycle, most noticeably at stages II/III.
  • We hypothesize either that subacute HD pretreatment compromises the ability of the Sertoli cells to eliminate x-ray-damaged germ cells or that germ cells are more resistant to x-ray-induced damage, having adapted to a less supportive environment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Soc Exp Biol Med. 2000 Nov;225(2):105-15 [11044252.001]
  • [Cites] Toxicol Sci. 2010 Oct;117(2):457-65 [20616210.001]
  • [Cites] Toxicol Sci. 2004 Jul;80(1):92-100 [15141104.001]
  • [Cites] Biol Reprod. 1983 Aug;29(1):257-70 [6615968.001]
  • [Cites] Toxicol Appl Pharmacol. 1988 Jan;92(1):18-27 [3341024.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Apr;137(2):141-8 [8661338.001]
  • [Cites] J Androl. 1996 Jul-Aug;17(4):394-402 [8889702.001]
  • [Cites] Radiat Res. 1997 Apr;147(4):457-67 [9092926.001]
  • [Cites] Endocrinology. 1997 May;138(5):2081-8 [9112408.001]
  • [Cites] Tissue Cell. 1997 Aug;29(4):487-93 [9281847.001]
  • [Cites] Endocrinology. 1999 Feb;140(2):852-8 [9927315.001]
  • [Cites] Endocrinology. 1999 Apr;140(4):1709-17 [10098507.001]
  • [Cites] Ann N Y Acad Sci. 1952 Nov 20;55(4):548-73 [13139144.001]
  • [Cites] J Natl Cancer Inst Monogr. 2005;(34):6-8 [15784812.001]
  • [Cites] Toxicol Sci. 2007 Jan;95(1):249-56 [17065434.001]
  • [Cites] Toxicol Pathol. 2007 Aug;35(5):719-27 [17763286.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8315-20 [18544648.001]
  • [Cites] Toxicol Pathol. 2008 Jun;36(4):552-9 [18467684.001]
  • [Cites] Toxicol Sci. 2010 Oct;117(2):466-74 [20616204.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:125-47 [12471174.001]
  • (PMID = 20616207.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES013660; United States / NIEHS NIH HHS / ES / 5 P42 ES013660
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hexanones; 0 / Radiation-Protective Agents; 110-13-4 / 2,5-hexanedione
  • [Other-IDs] NLM/ PMC2940404
  •  go-up   go-down


5. Chavers BM, Solid CA, Gilbertson DT, Collins AJ: Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States. J Am Soc Nephrol; 2007 Mar;18(3):952-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States.
  • Infection-related hospitalization (IH) incidence among US Medicare incident pediatric and adult dialysis and transplant patients within 3 yr of presentation was compared from 1996 to 2001: Hemodialysis (HD) patients (pediatric n = 1469; adult n = 305,323); peritoneal dialysis (PD) patients (pediatric n=982; adult n=27,119), and kidney transplant (KTx) patients (pediatric n=1108; adult n=31,663).
  • Cumulative incidence of IH at 36 mo for incident pediatric patients with ESRD during 1996 to 2001 was 39.9% in HD, 51.2% in PD, and 47.4% in KTx patients (HD or PD versus KTx, P<0.0001).
  • Cumulative incidence for adults was 52.6% in HD, 51.8% in PD, and 39.8% in KTx patients (HD or PD versus KTx, P<0.0001).
  • IH rates per 1000 patient-months were highest for pediatric KTx patients (adjusted rate ratio 1.53 versus HD and 1.90 versus PD, P<0.001 for each) and adult HD patients (adjusted rate ratio 1.20 versus KTx and 1.11 versus PD, P < 0.001 for each).
  • Within the first 36 mo of incidence, IH rates are highest for incident pediatric KTx patients compared with HD and PD patients, in contrast to findings for adult patients with ESRD.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17251389.001).
  • [ISSN] 1046-6673
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / N01-DK-9-2343
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


6. Hemphill SA, Kotevski A, Herrenkohl TI, Toumbourou JW, Carlin JB, Catalano RF, Patton GC: Pubertal stage and the prevalence of violence and social/relational aggression. Pediatrics; 2010 Aug;126(2):e298-305
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pubertal stage and the prevalence of violence and social/relational aggression.
  • OBJECTIVE: We examined associations between pubertal stage and violent adolescent behavior and social/relational aggression.
  • METHODS: The International Youth Development Study comprises statewide representative student samples in grades 5, 7, and 9 (N = 5769) in Washington State and Victoria, Australia, drawn as a 2-stage cluster sample in each state.
  • For social/relational aggression, there were weaker overall associations after adjustment, but these associations included an interaction between pubertal stage and age, and stronger associations with pubertal stage at younger age were shown (P = .003; midpuberty OR: 1.78 [95% CI: 1.20-2.63]; late puberty OR: 3.00 [95% CI: 1.95-4.63]).
  • Associations between pubertal stage and violent behavior and social/relational aggression remained after the inclusion of social contextual mediators in the analyses.
  • CONCLUSIONS: Pubertal stage was associated with higher rates of violent behavior and social/relational aggression, with the latter association seen only at younger ages.

  • MedlinePlus Health Information. consumer health - Family Issues.
  • MedlinePlus Health Information. consumer health - Puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Abnorm Child Psychol. 2002 Aug;30(4):311-26 [12108763.001]
  • [Cites] Aggress Behav. 2009 Mar-Apr;35(2):188-202 [19067362.001]
  • [Cites] J Adolesc Health. 2003 Oct;33(4):279-86 [14519570.001]
  • [Cites] Pediatrics. 2004 Sep;114(3):e300-6 [15342890.001]
  • [Cites] Arch Dis Child. 1969 Jun;44(235):291-303 [5785179.001]
  • [Cites] Arch Dis Child. 1970 Feb;45(239):13-23 [5440182.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1988 Nov;27(6):726-37 [3058677.001]
  • [Cites] Dev Psychobiol. 1989 Sep;22(6):633-43 [2792573.001]
  • [Cites] J Pers Soc Psychol. 1991 Jul;61(1):157-68 [1890586.001]
  • [Cites] J Adolesc Health. 1993 May;14(3):190-5 [8323929.001]
  • [Cites] Behav Neurosci. 1998 Oct;112(5):1152-66 [9829793.001]
  • [Cites] Child Psychiatry Hum Dev. 2005 Fall;36(1):73-94 [16049645.001]
  • [Cites] J Adolesc. 2006 Oct;29(5):709-20 [16324738.001]
  • [Cites] J Interpers Violence. 2007 Apr;22(4):386-405 [17369443.001]
  • [Cites] Lancet. 2007 Mar 31;369(9567):1130-9 [17398312.001]
  • [Cites] Health Educ Behav. 2007 Aug;34(4):634-50 [16740513.001]
  • [Cites] J Epidemiol Community Health. 2007 Sep;61(9):764-70 [17699529.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2008 Dec;47(12):1424-32 [18978636.001]
  • [Cites] Eval Rev. 2002 Dec;26(6):575-601 [12465571.001]
  • (PMID = 20624807.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA012140-05; None / None / / R24 HD042828-10; United States / NIDA NIH HHS / DA / R01-DA012140-05; United States / NIDA NIH HHS / DA / R01 DA012140; United States / NICHD NIH HHS / HD / R24 HD042828-10; United States / NIDA NIH HHS / DA / DA012140-05; United States / NICHD NIH HHS / HD / R24 HD042828
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS208354; NLM/ PMC2914838
  •  go-up   go-down


7. Zheng X, Zugates CT, Lu Z, Shi L, Bai JM, Lee T: Baboon/dSmad2 TGF-beta signaling is required during late larval stage for development of adult-specific neurons. EMBO J; 2006 Feb 8;25(3):615-27
FlyBase. FlyBase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baboon/dSmad2 TGF-beta signaling is required during late larval stage for development of adult-specific neurons.
  • The intermingling of larval functional neurons with adult-specific neurons during metamorphosis contributes to the development of the adult Drosophila brain.
  • We found that Baboon(Babo)/dSmad2-mediated TGF-beta signaling, known to be essential for remodeling of larval functional neurons, is also indispensable for proper morphogenesis of these adult-specific neurons.
  • We observe similar phenomena in other adult-specific neurons.
  • We further demonstrate that Babo/dSmad2 operates autonomously in individual neurons and specifically during the late larval stage.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1982 Feb 4;295(5848):405-7 [6799834.001]
  • [Cites] Development. 2004 Oct;131(20):5167-84 [15459108.001]
  • [Cites] Dev Biol. 1988 Jan;125(1):145-57 [3119399.001]
  • [Cites] Annu Rev Neurosci. 1990;13:183-94 [2183673.001]
  • [Cites] J Neurobiol. 1990 Oct;21(7):1072-84 [1979610.001]
  • [Cites] Development. 1991 Jan;111(1):79-88 [1901786.001]
  • [Cites] Cell. 1993 Jul 2;73(7):1323-37 [8324824.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9475-9 [8415726.001]
  • [Cites] Mol Cell Biol. 1994 Feb;14(2):944-50 [8289834.001]
  • [Cites] Genes Dev. 1994 Jan;8(2):133-46 [8299934.001]
  • [Cites] Development. 1993 Dec;119(4):1251-9 [8306887.001]
  • [Cites] Development. 1994 Jan;120(1):189-97 [8119126.001]
  • [Cites] Development. 1994 Jan;120(1):219-34 [8119129.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5972-6 [8016099.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5625-30 [7890683.001]
  • [Cites] Curr Opin Neurobiol. 1995 Feb;5(1):28-35 [7773002.001]
  • [Cites] Development. 1997 Jan;124(2):461-70 [9053322.001]
  • [Cites] Nature. 1997 Sep 4;389(6646):85-9 [9288972.001]
  • [Cites] Nature. 1997 Dec 4;390(6659):465-71 [9393997.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 24;1333(2):F105-50 [9395284.001]
  • [Cites] J Neurosci Res. 1998 Jan 15;51(2):139-46 [9469567.001]
  • [Cites] Genetics. 1998 Feb;148(2):801-13 [9504926.001]
  • [Cites] Science. 1998 Jul 31;281(5377):706-9 [9685266.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2354-70 [9694800.001]
  • [Cites] Mol Cell. 1998 Jul;2(1):109-20 [9702197.001]
  • [Cites] Nature. 1998 Aug 27;394(6696):909-13 [9732876.001]
  • [Cites] Cell. 1998 Sep 4;94(5):585-94 [9741623.001]
  • [Cites] Cell. 1998 Dec 11;95(6):737-40 [9865691.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):98-111 [9887103.001]
  • [Cites] Science. 1999 Feb 26;283(5406):1317-21 [10037600.001]
  • [Cites] Neuron. 1999 Mar;22(3):451-61 [10197526.001]
  • [Cites] Genes Cells. 1999 Feb;4(2):123-34 [10320478.001]
  • [Cites] Dev Biol. 1999 Jun 15;210(2):251-68 [10357889.001]
  • [Cites] Learn Mem. 1998 May-Jun;5(1-2):52-77 [10454372.001]
  • [Cites] Learn Mem. 1998 May-Jun;5(1-2):102-14 [10454375.001]
  • [Cites] Development. 1999 Sep;126(18):4065-76 [10457015.001]
  • [Cites] Neuron. 1999 Sep;24(1):127-41 [10677032.001]
  • [Cites] Neuron. 2000 Mar;25(3):549-61 [10774724.001]
  • [Cites] Neuron. 2000 Dec;28(3):807-18 [11163268.001]
  • [Cites] Neuron. 2002 Feb 14;33(4):529-43 [11856528.001]
  • [Cites] Neuron. 2002 Feb 14;33(4):545-58 [11856529.001]
  • [Cites] Neuron. 2002 Feb 14;33(4):559-71 [11856530.001]
  • [Cites] Development. 2002 Apr;129(8):1839-47 [11934850.001]
  • [Cites] Cell. 2003 Feb 7;112(3):303-15 [12581521.001]
  • [Cites] Neuron. 2003 May 8;38(3):389-401 [12741987.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Neuron. 2004 Sep 2;43(5):663-72 [15339648.001]
  • [Cites] J Comp Neurol. 1987 Jan 22;255(4):548-59 [3819030.001]
  • (PMID = 16437159.001).
  • [ISSN] 0261-4189
  • [Journal-full-title] The EMBO journal
  • [ISO-abbreviation] EMBO J.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / T32 HD007333; United States / NICHD NIH HHS / HD / HD07333
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / Smad2 Protein; 0 / Transforming Growth Factor beta; 104625-48-1 / Activins; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / Activin Receptors, Type I; EC 2.7.11.30 / Activin Receptors, Type II; EC 2.7.11.30 / put protein, Drosophila
  • [Other-IDs] NLM/ PMC1383542
  •  go-up   go-down


8. Andrikos E, Tseke P, Balafa O, Pappas M: Five-year survival in comparable HD and PD patients: one center's experience. Int J Artif Organs; 2008 Aug;31(8):737-41
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year survival in comparable HD and PD patients: one center's experience.
  • Several studies have yielded conflicting results regarding morbidity and mortality in peritoneal dialysis (PD) and hemodialysis (HD) patients.
  • We performed a retrospective analysis in end-stage renal disease (ESRD) patients in our department, who were equally distributed between HD and PD, in order to compare 5-year survival probabilities and hospitalization rates in the two modalities.
  • Of the total 94 new ESRD patients who initiated dialysis in our department from January 1995 to December 2000, 48 were allocated to PD and 46 to HD.
  • There were no significant differences regarding demographics and serious co-morbidities upon dialysis initiation between HD and PD patients.
  • Unadjusted 5-year survival probability in as-treated analysis was higher in PD patients (0.79 vs 0.6, p=0.04), whereas there was no significant difference in intent-to-treat analysis between HD and PD patients (p=0.5).
  • Despite the small number of patients included in our study, it seems that when HD and PD are both available in one department they have equivalent results regarding morbidity and mortality rates.
  • Therefore we suggest that, when possible, PD and HD should be equally offered to all ESRD patients.
  • [MeSH-minor] Adult. Aged. Female. Hospitalization. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825647.001).
  • [ISSN] 0391-3988
  • [Journal-full-title] The International journal of artificial organs
  • [ISO-abbreviation] Int J Artif Organs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Posadzy-Małaczyńska A, Wanic-Kossowska M, Tykarski A, Czekalski S, Głuszek J, Kosch M: [Vascular stiffness in chronic renal failure patients treated by hemodialysis]. Pol Arch Med Wewn; 2005 Nov;114(5):1072-8
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Sztywnosć duzych naczyń u chorych z przewlekła niewydolnościa nerek leczonych zabiegami hemodializ (HD).
  • Cardiovascular disease is a major cause of morbidity in patients with end-stage renal failure.
  • Arterial stiffness measured by pulse wave velocity (PWV) is an independent risk factor for morbidity in end stage renal failure patients.
  • In 20 chronic renal failure patients treated by hemodialysis (HD) we assessed the PWV of the carotic artery as well as artery diameter and distensibility, systolic pressure (SBP), diastolic pressure (DBP), pulse pressure (PP), and basal biochemical parameters and compared them with the values determined in 20 healthy controls of comparable age.
  • PWV and PP are significantly (p < 0.001, p < 0.05) higher and distensibility of the carotic artery was significantly lower (p < 0.001) compared to a control group SBP and DBP were < 140/90 mmHg in HD patients (high normotensive range) but were significantly (p < 0.05) higher than in a control group.
  • In HD patients PP was correlated with arterial distensibility r = -0.600 (p < 0.005), and systolic artery rice r = -0.408 (p < 0.05).
  • [MeSH-minor] Adult. Aorta / physiopathology. Blood Pressure / physiology. Cardiovascular Diseases / etiology. Cardiovascular Diseases / physiopathology. Cross-Sectional Studies. Elasticity. Female. Humans. Hypertrophy, Left Ventricular / etiology. Male. Pulsatile Flow / physiology. Renal Dialysis. Risk Factors. Vascular Capacitance. Vascular Resistance

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16789505.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


10. Park SB, Sung KR, Kang SY, Kim KR, Kook MS: Comparison of glaucoma diagnostic Capabilities of Cirrus HD and Stratus optical coherence tomography. Arch Ophthalmol; 2009 Dec;127(12):1603-9
MedlinePlus Health Information. consumer health - Optic Nerve Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of glaucoma diagnostic Capabilities of Cirrus HD and Stratus optical coherence tomography.
  • Our findings suggest that spectral-domain technology of OCT may offer an improved capability of early-stage glaucoma detection.
  • [MeSH-minor] Adult. Aged. Area Under Curve. Female. Humans. Intraocular Pressure. Likelihood Functions. Male. Middle Aged. Prospective Studies. ROC Curve. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Glaucoma.
  • MedlinePlus Health Information. consumer health - Glaucoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008715.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Nardone R, Lochner P, Marth R, Ausserer H, Bratti A, Tezzon F: Abnormal intracortical facilitation in early-stage Huntington's disease. Clin Neurophysiol; 2007 May;118(5):1149-54
Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal intracortical facilitation in early-stage Huntington's disease.
  • OBJECTIVE: It is known from neuropathological and imaging studies that the neuronal degeneration in Huntington's disease (HD) is already quite severe when the first symptoms of the disease become clinically evident.
  • This study was aimed at detecting neurophysiological changes, as assessed by means of transcranial magnetic stimulation (TMS), involved in the early pathogenesis of the neurodegeneration in HD.
  • METHODS: Motor cortex excitability was examined in 12 patients with HD in the early clinical stage of the disease and in 15 age-matched control subjects, using a range of TMS protocols.
  • RESULTS: The early-stage HD patients showed a statistically significant reduction in ICF.
  • CONCLUSIONS: Our findings provide neurophysiological evidence that changes in motor function are present in the early HD.
  • Since ICF is thought to depend upon the activity of intracortical glutamatergic excitatory circuits, the results of our study support the theory that altered NMDA receptor function plays an important role in the pathogenesis of HD.
  • SIGNIFICANCE: These findings may provide clues to the underlying pathophysiology of the disease.
  • A more complete understanding of the changes in motor cortex excitability that occur early in the course of HD will lead to a better definition of the disease process and may allow earlier diagnosis and intervention.
  • [MeSH-major] Huntington Disease / physiopathology. Motor Cortex / physiopathology
  • [MeSH-minor] Action Potentials / physiology. Adult. Disease Progression. Electromyography. Female. Glutamic Acid / physiology. Humans. Male. Middle Aged. Neural Conduction / physiology. Transcranial Magnetic Stimulation

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17336146.001).
  • [ISSN] 1388-2457
  • [Journal-full-title] Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  • [ISO-abbreviation] Clin Neurophysiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 3KX376GY7L / Glutamic Acid
  •  go-up   go-down


12. Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, Pober M, Hinterberger W, Hausmaninger H, Heistinger M, Ulsperger E, Karlhuber S, Schwinger W, Lindner B: Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). Ann Hematol; 2005 Jul;84(7):462-73
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
  • Between 1990 and 2001, 68 patients with advanced Hodgkin's disease (HD) and 86 patients classified as low-/intermediate-grade B non-Hodgkin's lymphoma (NHL) were reported to the Austrian Stem Cell Transplantation Registry (ASCTR).
  • Following autologous stem cell transplantation (SCT) for HD, overall survival was 56% [95% confidence interval (CI): 40-72%] with a disease-/progression-free survival of 49%, reaching a plateau at 5 years.
  • Using multivariate Cox regression analysis BEAM conditioning (carmustine, cytarabine, etoposide and melphalan) was predictive for favourable outcome, better disease-/progression-free survival and a significantly lower risk for relapse.
  • Overall survival for NHL patients was 45% (95% CI: 26-64%) with a disease-/progression-free survival of 26% at 7 years.
  • In the multivariate Cox regression analysis stage of disease at time of SCT was the most powerful parameter for overall survival, disease-/progression-free survival and relapse.
  • Mantle cell lymphoma, greater than or equal to three lines of previous therapy, and a conditioning regimen other than BEAM were also predictive for death.
  • Because of the high risk of relapse/progression in both disease categories and the additional high rate of second malignancies in HD patients, allogeneic stem cells should be considered a valuable alternative for selected patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / mortality. Hodgkin Disease / therapy. Transplantation, Autologous
  • [MeSH-minor] Adolescent. Adult. Austria. Child. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Recurrence. Registries. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726362.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Powell SF, Dudek AZ: Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):e20007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma.
  • : e20007 Background: HD IL-2 has been shown to produce durable responses in patients with metastatic melanoma.
  • METHODS: A retrospective analysis was performed all adult patients with Stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at our institution.
  • HD IL-2 was given I.V. every eight hours as a bolus over 15 minutes at a dose of 600,000 IU/kg.
  • RESULTS: A total of 15 patients with metastatic melanoma had been treated with HD IL-2 at our institution.
  • Complete response (CR) was seen in 6.67% (N=1), partial response (PR) in 6.67% (N=1), mixed response (MR) in 6.67% (N=1), and stable disease (SD) in 13.33% (N=2).
  • Average time to disease progression (TTDP) was 5.67 months in those with a PR or SD.
  • Two patients with brain metastases had subsequently complete resolution of the brain lesions after HD IL-2 therapy.
  • One of these patients has a CR and is disease free 34 months out from therapy.
  • The other had PR and is currently alive with disease, but has no recurrence of the brain lesion after over 19 months.
  • On average patients tolerated 10.5 HD IL-2 doses with the first course and 8.8 doses with the second course.
  • HD IL-2 has typically been avoided in patients with brain metastases due to concern for neurologic complications from the capillary leak syndrome caused by treatment.
  • We propose further evaluation of this ineligibility for HD IL-2, since carefully selected patients with brain metastases may derive benefit from this treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A: Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol; 2006 Jan;78(1):1-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease.
  • BACKGROUND: Short course chemotherapy followed by radiotherapy is a standard treatment for early Hodgkin's disease.
  • PATIENTS AND METHODS: From 1980 to 1996, 61 patients with stage I and II supradiaphragmatic Hodgkin's disease were treated with chemotherapy alone at the Royal Marsden Hospital.
  • Twenty patients (83%) relapsed in the initially involved sites of disease and this was the sole site of recurrence in 11 (45%) of patients.
  • Review of detailed imaging data (available in 9 out of 11 patients with recurrences in initial sites of disease) showed that the relapses were always in the initially involved nodes.
  • CONCLUSION: After chemotherapy alone in early stage HD most initial recurrences are nodal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309770.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


15. Tickoo SK, dePeralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, Moch H, Amin MB: Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol; 2006 Feb;30(2):141-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.
  • Most (up to 71%) of renal cell neoplasms occurring in patients with end-stage renal disease (ESRD), particularly with acquired cystic disease of the kidney (ACDK), have been reported to be papillary renal cell carcinoma (RCC).
  • The more common tumor that we have designated as "acquired cystic disease-associated RCC" was seen as the dominant mass in 24 (36%) of 66 of the kidneys, and it formed the most common tumor type among the smaller nondominant masses, as well.
  • The other category was "clear-cell papillary RCC of the end-stage kidneys," present as the dominant mass in 15 (23%) of the 66 kidneys and occurring in both the ACDK and noncystic ESRD.
  • Only the acquired cystic disease-associated RCC showed lymph node metastases in 2 cases and sarcomatoid features in 2 more cases.
  • One of the latter 2 died with widespread metastatic disease within 34 months of nephrectomy.
  • Acquired cystic disease-associated RCC is the commonest tumor subtype in ESRD, and biologically it appears to be more aggressive than the other tumor subtypes in ESRD.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434887.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Chambon JP, Alarcon B, N'Guyen HD, Gaillard R, Pagniez D, Dumont A: [Results of infrainguinal revascularization in patients with end-stage renal disease]. Ann Chir; 2005 Jan;130(1):26-31
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of infrainguinal revascularization in patients with end-stage renal disease].
  • OBJECTIVES: The aim of this retrospective study was to evaluate the efficacy of bypass in patients with endstage renal disease (ESRD) and to determine predictive factors and precise bypass indications.
  • METHOD: Forty one patients with ESRD underwent 50 bypass, 6 limbs were stage II and 44 stage III or IV according to Leriche and Fontaine classification.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Inguinal Canal / blood supply. Inguinal Canal / surgery. Kidney / blood supply. Male. Middle Aged. Morbidity. Prognosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15664373.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


17. Civilibal M, Caliskan S, Adaletli I, Oflaz H, Sever L, Candan C, Canpolat N, Kasapcopur O, Kuruoglu S, Arisoy N: Coronary artery calcifications in children with end-stage renal disease. Pediatr Nephrol; 2006 Oct;21(10):1426-33
Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coronary artery calcifications in children with end-stage renal disease.
  • Coronary artery calcification (CAC) is common in adults with end-stage renal disease (ESRD), but little is known about the prevalence and the extent of it in children.
  • We used multidetector spiral computed tomography (MDCT), echocardiography, and carotid and brachial high-resolution ultrasonography to screen for the presence and predisposing factors of CAC in 53 children with ESRD [15 hemodialysis (HD) patients, 24 peritoneal dialysis (PD) patients, and 14 renal transplant (rTx) recipients].
  • CAC was present in 15% of patients (three HD patients, three PD patients, and two rTx).
  • [MeSH-major] Calcinosis / epidemiology. Calcinosis / etiology. Coronary Artery Disease / epidemiology. Coronary Artery Disease / etiology. Kidney Failure, Chronic / complications
  • [MeSH-minor] Adolescent. Adult. Brachial Artery / ultrasonography. Calcium / metabolism. Carotid Arteries / ultrasonography. Child. Female. Humans. Male. Peritoneal Dialysis / methods. Phosphate-Binding Proteins / adverse effects. Phosphorus / blood. Predictive Value of Tests. Prevalence. Regression Analysis. Risk Factors. Tomography, Spiral Computed

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821026.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Phosphate-Binding Proteins; 27YLU75U4W / Phosphorus; SY7Q814VUP / Calcium
  •  go-up   go-down


18. Paneni F, Gregori M, Ciavarella GM, Sciarretta S, De Biase L, Marino L, Tocci G, Principe F, Domenici A, Luciani R, Punzo G, Menè P, Volpe M: Right ventricular dysfunction in patients with end-stage renal disease. Am J Nephrol; 2010;32(5):432-8
MedlinePlus Health Information. consumer health - Pulmonary Hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Right ventricular dysfunction in patients with end-stage renal disease.
  • BACKGROUND: While chronic dialysis treatment has been suggested to increase pulmonary pressure values, right ventricular dysfunction (RVD) is a major cause of death in patients with end-stage renal disease.
  • METHODS: We examined 220 subjects grouped as follows: healthy controls (n = 100), peritoneal dialysis (PD; n = 26), hemodialysis (HD) with radial arteriovenous fistula (AVF; n = 62), and HD with brachial AVF (n = 32).
  • TDI indices of right ventricular function were more impaired in HD patients, particularly in those with brachial AVF.
  • RVD, assessed by TDI myocardial performance index, was higher in HD patients compared with PD patients (71.3 vs. 34.6%, p < 0.001).
  • CONCLUSIONS: Compared to DP, HD increases the risk of RVD, particularly in the presence of brachial AVF.
  • TDI may detect early functional failure of the right ventricle in HD patients.
  • [MeSH-minor] Adult. Aged. Arteriovenous Shunt, Surgical / adverse effects. Brachial Artery / surgery. Echocardiography, Doppler. Female. Humans. Incidence. Male. Middle Aged. Prevalence. Radial Artery / surgery. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20881380.001).
  • [ISSN] 1421-9670
  • [Journal-full-title] American journal of nephrology
  • [ISO-abbreviation] Am. J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Bayraktar G, Kurtulus I, Kazancioglu R, Bayramgurler I, Cintan S, Bural C, Bozfakioglu S, Issever H, Yildiz A: Oral health and inflammation in patients with end-stage renal failure. Perit Dial Int; 2009 Jul-Aug;29(4):472-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral health and inflammation in patients with end-stage renal failure.
  • BACKGROUND/AIMS: End-stage renal disease (ESRD) patients have an increased risk of atherosclerotic complications.
  • In both hemodialysis (HD) patients and the general population, it has become evident that inflammation plays an important role in the pathogenesis of atherosclerotic complications.
  • Our aim was to analyze and compare salivary flow rate (SFR), salivary pH (SpH), salivary buffering capacity (SBC), and DMFT index and plaque index (PI) values in PD patients to HD patients and healthy controls (C) and establish the relationship between these parameters and C-reactive protein (CRP).
  • METHODS: 76 PD patients, 100 HD patients, and 111 Cs were included in the study.
  • RESULTS: No statistically significant differences were found in age or gender distribution among PD, HD, and C groups.
  • There was also no significant difference in time on dialysis between PD and HD groups.
  • SFR was significantly lower in the PD and HD groups than in the C group (1.30 +/- 0.83 and 0.70 +/- 0.32 vs 1.64 +/- 0.45 mL/min) and lower in the HD than in the PD group (p < 0.001).
  • SpH (8.35 +/- 0.43 and 8.12 +/- 0.74 vs 7.16 +/- 0.76) and SBC (7.39 +/- 0.47 and 6.82 +/- 0.70 vs 5.08 +/- 0.73) were significantly higher in the PD and HD groups than in the C group and higher in the PD than in the HD group (p < 0.05 and p < 0.001 respectively).
  • The numbers of filled teeth were significantly higher in the PD than in the HD and C groups (p < 0.001).
  • DMFT index was significantly higher in the PD than in the HD group (p < 0.001).
  • Finally, PI values were significantly higher in the PD and HD groups than in the C group (p < 0.001) and higher in the HD than in the PD group, although this was not statistically significant.
  • In the present study, we also found higher CRP values in HD than in PD patients and a positive correlation between CRP and PI values in PD patients.
  • CONCLUSIONS: PD patients have higher SFR, SpH, and SBC values than HD patients; however, higher DMFT index and higher numbers of filled teeth were observed in PD patients.
  • [MeSH-minor] Adult. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors. Saliva / metabolism


20. Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA: The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol; 2005 Nov;57(11):1407-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.
  • Inflammation is strongly associated with malnutrition and cardiovascular risk in patients with chronic renal failure on haemodialysis (HD).
  • The acute-phase inflammatory response, defined by the increased synthesis of positive acute-phase proteins, is stimulated by the production of such cytokines as interleukin 6 (IL-6), interleukin 1 (IL-1) and tumour necrosis factor-alpha TNF-alpha The availability of cytokine antagonists allows testing of the hypothesis that suppression of inflammation reverses the malnutrition-inflammation syndrome in HD patients.
  • Its metabolism in HD patients is unknown.
  • In a study designed to test the safety and pharmacokinetics of etanercept in HD patients, etanercept was administered to six HD patients with albumin levels above 4.2 g dL(-1) and C-reactive protein levels <5 mg L(-1) (five men, one woman, age range 34-59 years).
  • Concentrations were compared graphically to assess whether, firstly, dialysis affects etanercept apparent clearance and, secondly, etanercept kinetics were similar between HD patients and the more extensively studied psoriasis population with normal renal function (PS).
  • The second stage examined model-based parameter predictions of the terminal elimination rate constant (k) for HD patients.
  • Steady-state etanercept levels were comparable between HD and PS patients.
  • Treatment with HD had no effect on etanercept levels.
  • When etanercept was discontinued, the terminal rate constant for HD patients was not significantly different from that observed in PS patients.
  • The pharmacokinetics of etanercept in patients with chronic renal failure on HD are similar to patients with normal renal function.
  • It is, therefore, feasible to administer etanercept to HD patients without adjusting the dose.
  • [MeSH-minor] Adult. Etanercept. Female. Humans. Male. Metabolic Clearance Rate. Middle Aged. Models, Biological. Renal Dialysis

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259772.001).
  • [ISSN] 0022-3573
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; OP401G7OJC / Etanercept
  •  go-up   go-down


21. Ascerić M, Mulabegović N, Nuhbegović S, Nadarević A, Mujcinagić-Vrabac M: Antihypertensive treatment in patients with end-stage renal disease. Bosn J Basic Med Sci; 2005 Nov;5(4):22-5
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antihypertensive treatment in patients with end-stage renal disease.
  • Arterial hypertension is a common finding in patients with end stage renal disease (80% patients are hypertensive).
  • We studied 80 hypertensive adult patients who had been on regular haemodialysis treatment for at least 12 months (average duration of 41 months).
  • Blood pressure measurements before and after HD sessions were performed for each patient.

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351593.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Bosnia and Herzegovina
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Antihypertensive Agents; 0 / Indoles; 1T0N3G9CRC / trandolapril
  •  go-up   go-down


22. Raj DS, Dominic EA, Pai A, Osman F, Morgan M, Pickett G, Shah VO, Ferrando A, Moseley P: Skeletal muscle, cytokines, and oxidative stress in end-stage renal disease. Kidney Int; 2005 Nov;68(5):2338-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skeletal muscle, cytokines, and oxidative stress in end-stage renal disease.
  • BACKGROUND: End-stage renal disease (ESRD) is a state of microinflammation, with increased activation of cytokines and augmented oxidative stress.
  • While peripheral blood mononuclear cells are an established source of reactive oxygen species and inflammatory cytokines during hemodialysis (HD), skeletal muscle is also capable of generating these biomolecules.
  • ESRD patients were studied before (pre-HD) and during HD. mRNA levels of cytokines, heme oxygenase-1 (HO-1), and suppressors of cytokine signaling-2 (SOCS-2) were quantitated in the skeletal muscle by real-time polymerase chain reaction (PCR).
  • RESULTS: Arterial concentration of MDA (pmol/mL) was higher pre-HD (325.5 +/- 19.6) compared to controls (267.7 +/- 14.7), but decreased intradialysis (248.8 +/- 16.1) (P < 0.01).
  • CP concentration (nmol/mg protein) in the artery was significantly higher pre-HD (2.29 +/- 0.09) than in controls (1.92 +/- 0.05), and remained stable during HD (2.23 +/- 0.07).
  • Plasma cytokines increased to a variable degree in the artery and vein during HD.
  • mRNA levels of IL-6 (0.028 +/- 0.02 vs. 6.69 +/- 0.21), HO-1 (0.96 +/- 0.01 vs. 5.08 +/- 1.11), and SOCS-2 (0.63 +/- 0.12 vs. 0.82 +/- 0.14) in the muscle increased during HD (P < 0.01).
  • Immunohistochemical studies confirmed the increase in IL-6 protein in the skeletal muscle during HD.
  • CONCLUSION: Skeletal muscle may also contribute to the circulating plasma IL-6 and increased oxidative stress during HD.
  • [MeSH-minor] Adult. Biopsy. Blood Proteins / metabolism. Gene Expression / immunology. Humans. Hypertension, Renal / immunology. Hypertension, Renal / metabolism. Interleukin-1 / blood. Interleukin-1 / genetics. Interleukin-10 / blood. Interleukin-10 / genetics. Interleukin-6 / blood. Interleukin-6 / genetics. Malondialdehyde / blood. Middle Aged. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221238.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01 RR00997
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Cytokines; 0 / Interleukin-1; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 4Y8F71G49Q / Malondialdehyde
  •  go-up   go-down


23. Sullivan MA, Rothenberg JL, Vosburg SK, Church SH, Feldman SJ, Epstein EM, Kleber HD, Nunes EV: Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict; 2006 Mar-Apr;15(2):150-9
Hazardous Substances Data Bank. METHADONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial.
  • An uncontrolled Stage I pilot trial (N = 47) of BNT was conducted.

  • MedlinePlus Health Information. consumer health - Heroin.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NALTREXONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595353.001).
  • [ISSN] 1055-0496
  • [Journal-full-title] The American journal on addictions
  • [ISO-abbreviation] Am J Addict
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / DA00288; United States / NIDA NIH HHS / DA / DA00433; United States / NIDA NIH HHS / DA / DA10746
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Narcotic Antagonists; 5S6W795CQM / Naltrexone; UC6VBE7V1Z / Methadone
  •  go-up   go-down


24. Yeh CN, Chen MF, Jan YY: Laparoscopic cholecystectomy for 58 end stage renal disease patients. Surg Endosc; 2005 Jul;19(7):915-8
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic cholecystectomy for 58 end stage renal disease patients.
  • Because hemorrhage, infection, and delayed wound healing are the main causes of death after surgery for end-stage renal disease (ESRD), laparoscopic surgery is risky for ESRD patients.
  • METHOD: From January 1994 to December 2003, the medical records of 58 ESRD patients under regular hemodialysis (HD) with gallbladder lesions undergoing LC were reviewed (ESRD-LC).
  • RESULTS: Of 6,240 patients with gallbladder lesions undergoing LC, 58 (0.93%) had ESRD with regular HD.
  • The ESRD-LC group clearly exhibited older age, higher frequency of associated disease, lower hemoglobin and platelet count, and elevated alkaline phosphatase, blood urea nitrogen, and creatinine values.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholecystitis / epidemiology. Cholecystitis / surgery. Comorbidity. Creatinine / blood. Female. Gallstones / epidemiology. Gallstones / surgery. Humans. Male. Middle Aged. Multivariate Analysis. Renal Dialysis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868265.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


25. Rolla G, Bruno M, Bommarito L, Heffler E, Ferrero N, Petrarulo M, Bagnis C, Bugiani M, Guida G: Breath analysis in patients with end-stage renal disease: effect of haemodialysis. Eur J Clin Invest; 2008 Oct;38(10):728-33
Hazardous Substances Data Bank. Ammonia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breath analysis in patients with end-stage renal disease: effect of haemodialysis.
  • BACKGROUND: There is no agreement about exhaled nitric oxide (FE(NO)) and its change after haemodialysis (HD) in end-stage renal disease (ESRD) patients.
  • To comprehensively assess NO production in the respiratory system, NO metabolites in exhaled breath condensate (EBC) needs to be measured in addition to FE(NO), taking into account the influence on these markers of airway pH, which may be regulated by ammonia (NH3+), present in large amounts in the breath of ESRD patients and removed by HD.
  • STUDY DESIGN: FE(NO) and NO metabolites (NOx, NO2-,NO3- ), pH and NH3+ in EBC were measured in 12 ESRD patients, before and after HD.
  • HD caused a mild significant decrease of FE(NO), and normalization of NH3+, NOx, NO2- and pH.
  • A significant positive relationship between EBC-pH and EBC-NH3+ before and after HD (r(2) = 0.65, P = 0.000) was observed, explaining higher than normal EBC-pH before HD, while no relationship was found between EBC-pH and FE(NO) or NO metabolites.
  • CONCLUSION: Oxidative stress, and not EBC-pH, is the most probable cause of increased NO metabolites in ESRD patients before HD.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ammonia / analysis. Biomarkers / analysis. Case-Control Studies. Female. Humans. Hydrogen-Ion Concentration. Male. Middle Aged. Nitrates / analysis. Nitrites / analysis. Nitrogen Dioxide / analysis. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. Nitrogen dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837798.001).
  • [ISSN] 1365-2362
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Nitrates; 0 / Nitrites; 31C4KY9ESH / Nitric Oxide; 7664-41-7 / Ammonia; S7G510RUBH / Nitrogen Dioxide
  •  go-up   go-down


26. Raj DS, Welbourne T, Dominic EA, Waters D, Wolfe R, Ferrando A: Glutamine kinetics and protein turnover in end-stage renal disease. Am J Physiol Endocrinol Metab; 2005 Jan;288(1):E37-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutamine kinetics and protein turnover in end-stage renal disease.
  • We studied the intracellular amino acid transport kinetics and protein turnover in nine end-stage renal disease (ESRD) patients and eight controls by use of stable isotopes of phenylalanine, alanine, and glutamine.
  • Muscle protein breakdown was more than synthesis (nmol.min(-1).100 ml leg(-1)) during hemodialysis (HD) (169.8 +/- 20.0 vs. 125.9 +/- 21.8, P < 0.05) and in controls (126.9 +/- 6.9 vs. 98.4 +/- 7.5, P < 0.05), but synthesis and catabolism were comparable pre-HD (100.7 +/- 15.7 vs. 103.4 +/- 14.8).
  • Whole body protein catabolism decreased by 15% during HD.
  • Branched-chain amino acid catabolism (191.8 +/- 63.4 vs. -59.1 +/- 42.9) and nonprotein glutamate disposal (347.0 +/- 46.3 vs. 222.3 +/- 43.6) increased intradialysis compared with pre-HD (nmol.min(-1).100 ml leg(-1), P < 0.01).
  • The mRNA levels of glutamine synthase (1.45 +/- 0.14 vs. 0.33 +/- 0.08, P < 0.001) and branched-chain keto acid dehydrogenase-E2 (3.86 +/- 0.48 vs. 2.14 +/- 0.27, P < 0.05) in the muscle increased during HD.
  • Thus intracellular concentrations of alanine and glutamine are maintained during HD by augmented release of the amino acids from muscle protein catabolism.
  • [MeSH-minor] Adult. Alanine / metabolism. Arteries. Female. Humans. Male. Middle Aged. Models, Biological. Muscle, Skeletal / metabolism. Phenylalanine / metabolism. Renal Dialysis. Veins

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15265763.001).
  • [ISSN] 0193-1849
  • [Journal-full-title] American journal of physiology. Endocrinology and metabolism
  • [ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR-00997
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins; 3KX376GY7L / Glutamic Acid; 47E5O17Y3R / Phenylalanine; OF5P57N2ZX / Alanine
  •  go-up   go-down


27. Xiao T, Xia LX, Yang ZH, He CD, Gao XH, Chen HD: Narrow-band ultraviolet B phototherapy for early stage mycosis fungoides. Eur J Dermatol; 2008 Nov-Dec;18(6):660-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrow-band ultraviolet B phototherapy for early stage mycosis fungoides.
  • Recently there have been some reports concerned the treatment of early stage mycosis fungoides (MF) with narrow-band ultraviolet B (NB-UVB) phototherapy.
  • Our aim was to evaluate the effect of a twice weekly regimen of NB-UVB phototherapy in the treatment of early-stage MF.
  • Eight patients with early stage MF received NB-UVB phototherapy twice weekly.
  • The twice weekly regimen of NB-UVB phototherapy is effective and well-tolerated in the treatment of early stage MF.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955199.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


28. Studinger P, Lénárd Z, Mersich B, Reusz GS, Kollai M: Determinants of baroreflex function in juvenile end-stage renal disease. Kidney Int; 2006 Jun;69(12):2236-42
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of baroreflex function in juvenile end-stage renal disease.
  • Arterial baroreflex sensitivity (BRS) is markedly reduced in middle-aged patients with end-stage renal disease (ESRD), due to the combined effects of aging, arterial stiffening, and autonomic neuropathy.
  • We studied 42 subjects (9-30 years): 14 patients on maintenance hemodialysis (HD), 14 renal transplant recipients (RT), and 14 healthy control subjects (C).
  • BRS was markedly reduced in HD as compared to C (10.0+/-4.2 vs 25.7+/-5.9 ms/mm Hg); spontaneous indices were reduced to similar extent.
  • Carotid artery stiffness was approximately 50% higher in HD than in C and was inversely related to BRS.
  • Heart rate variability was also compromised in HD, and was directly related to spontaneous indices.
  • Decreased baroreflex function in juvenile HD is partly due to loss of carotid artery elasticity and partly due to impaired heart rate variability.
  • [MeSH-minor] Adolescent. Adult. Aging / physiology. Blood Pressure / physiology. Carotid Arteries / physiopathology. Case-Control Studies. Child. Cross-Sectional Studies. Elasticity. Heart Rate / physiology. Humans. Kidney Transplantation / physiology. Renal Dialysis

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16672915.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Aslam S, Santha T, Leone A, Wilcox C: Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int; 2006 Dec;70(12):2109-15
Hazardous Substances Data Bank. AMLODIPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.
  • Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) treatment have a markedly shortened life expectancy in large part owing to cardiovascular disease (CVD), not explained by established risk factors.
  • We conclude that hypertensive patients with ESRD receiving HD have evidence of extensive oxidation of lipids, thiols, proteins, and nucleic acids and methylation of arginine that could contribute to CVD.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Pressure / drug effects. Cross-Over Studies. Female. Humans. Hypertension, Renal / drug therapy. Hypertension, Renal / metabolism. Male. Methylation / drug effects. Middle Aged. Oxidative Stress / drug effects. Renal Dialysis. Valsartan

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VALSARTAN .
  • Hazardous Substances Data Bank. L-Valine .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Kidney Int. 2006 Dec;70(12):2053-5 [17136131.001]
  • (PMID = 17063175.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR020359
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Calcium Channel Blockers; 0 / Tetrazoles; 1J444QC288 / Amlodipine; 30315-93-6 / N,N-dimethylarginine; 80M03YXJ7I / Valsartan; 94ZLA3W45F / Arginine; HG18B9YRS7 / Valine
  •  go-up   go-down


30. O'Donnell BF, Blekher TM, Weaver M, White KM, Marshall J, Beristain X, Stout JC, Gray J, Wojcieszek JM, Foroud TM: Visual perception in prediagnostic and early stage Huntington's disease. J Int Neuropsychol Soc; 2008 May;14(3):446-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visual perception in prediagnostic and early stage Huntington's disease.
  • Disturbances of visual perception frequently accompany neurodegenerative disorders but have been little studied in Huntington's disease (HD) gene carriers.
  • We used psychophysical tests to assess visual perception among individuals in the prediagnostic and early stages of HD.
  • The sample comprised four groups, which included 201 nongene carriers (NG), 32 prediagnostic gene carriers with minimal neurological abnormalities (PD1); 20 prediagnostic gene carriers with moderate neurological abnormalities (PD2), and 36 gene carriers with diagnosed HD.
  • Patients with HD showed impaired contrast sensitivity for moving gratings.
  • These findings suggest that early stage HD disrupts visual functions associated with the magnocellular pathway.
  • However, these changes are only observed in individuals diagnosed with HD or who are in the more symptomatic stages of prediagnostic HD.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 1995 Jun;45(6):1217-8 [7783894.001]
  • [Cites] J Neural Transm (Vienna). 2007 Mar;114(3):367-72 [17024326.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] Ann Neurol. 1996 Sep;40(3):387-98 [8797528.001]
  • [Cites] Brain. 1996 Oct;119 ( Pt 5):1647-65 [8931587.001]
  • [Cites] J Neurol. 1996 Mar;243(3):286-92 [8936361.001]
  • [Cites] Spat Vis. 1997;10(4):479-84 [9176958.001]
  • [Cites] J Int Neuropsychol Soc. 2007 May;13(3):539-43 [17445303.001]
  • [Cites] Arch Neurol. 1997 Sep;54(9):1081-8 [9311351.001]
  • [Cites] Clin Neurosci. 1998;5(2):102-6 [10785835.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Dec;69(6):773-9 [11080230.001]
  • [Cites] Brain. 2001 Feb;124(Pt 2):310-21 [11157558.001]
  • [Cites] Neurology. 2002 Mar 12;58(5):695-701 [11889230.001]
  • [Cites] J Abnorm Psychol. 2003 Feb;112(1):28-37 [12653411.001]
  • [Cites] Science. 2003 May 2;300(5620):812-5 [12730605.001]
  • [Cites] Mov Disord. 2003 Sep;18(9):1027-34 [14502670.001]
  • [Cites] Neurology. 2003 Dec 23;61(12):1702-6 [14694033.001]
  • [Cites] Clin Genet. 2004 Apr;65(4):267-77 [15025718.001]
  • [Cites] Neuropsychopharmacology. 2004 Jul;29(7):1386-94 [15054473.001]
  • [Cites] Neurology. 2004 Sep 28;63(6):989-95 [15452288.001]
  • [Cites] J Acoust Soc Am. 1971 Feb;49(2):Suppl 2:467+ [5541744.001]
  • [Cites] Neurology. 1978 Jan;28(1):95-7 [145551.001]
  • [Cites] Electroencephalogr Clin Neurophysiol. 1981 Jun;51(6):666-70 [6165568.001]
  • [Cites] Science. 1988 May 6;240(4853):740-9 [3283936.001]
  • [Cites] Brain Res. 1990 Feb 12;509(1):156-60 [2306632.001]
  • [Cites] Mov Disord. 1991;6(2):127-32 [1829137.001]
  • [Cites] Ann Neurol. 1992 Oct;32(4):526-34 [1280937.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Vision Res. 1993 Dec;33(18):2589-609 [8296455.001]
  • [Cites] Ann Neurol. 1995 May;37(5):657-64 [7755361.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):172-7 [9489526.001]
  • [Cites] J Abnorm Psychol. 1998 Feb;107(1):49-62 [9505038.001]
  • [Cites] Annu Rev Neurosci. 1999;22:145-73 [10202535.001]
  • [Cites] Vision Res. 2005 Apr;45(8):1013-20 [15695186.001]
  • [Cites] Cogn Behav Neurol. 2005 Jun;18(2):102-7 [15970729.001]
  • [Cites] Neuropsychology. 2005 Nov;19(6):728-38 [16351348.001]
  • [Cites] Neurology. 2005 Dec 27;65(12):1907-13 [16282276.001]
  • [Cites] Neurology. 2006 Aug 8;67(3):394-9 [16855205.001]
  • [Cites] Schizophr Res. 2006 Sep;86(1-3):89-98 [16829048.001]
  • [Cites] Clin Chem. 1996 May;42(5):773-4 [8653908.001]
  • (PMID = 18419843.001).
  • [ISSN] 1469-7661
  • [Journal-full-title] Journal of the International Neuropsychological Society : JINS
  • [ISO-abbreviation] J Int Neuropsychol Soc
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS042659-05; United States / NIMH NIH HHS / MH / MH062150-01A1; United States / NIMH NIH HHS / MH / 1 R01 MH62150-01; United States / NINDS NIH HHS / NS / R01 NS42659; United States / NIMH NIH HHS / MH / R01 MH062150-01A1; United States / NINDS NIH HHS / NS / N01-NS-2326; United States / NINDS NIH HHS / NS / R01 NS042659; United States / NIMH NIH HHS / MH / R01 MH062150; United States / NINDS NIH HHS / NS / NS042659-05
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS81425; NLM/ PMC2643869
  •  go-up   go-down


31. Kim YB, Lee IJ, Kim SY, Kim JW, Yoon HI, Kim SW, Kim S, Kim YT, Suh CO, Kim GE: Tumor heterogeneity of FIGO stage III carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1323-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor heterogeneity of FIGO stage III carcinoma of the uterine cervix.
  • PURPOSE: The purpose of this study was to analyze tumor heterogeneity based on tumor extent and suggest reappraisal of the system of the International Federation of Gynecology and Obstetrics (FIGO) for Stage III carcinoma of the uterine cervix from a radiotherapeutic viewpoint.
  • METHODS AND MATERIALS: Between 1986 and 2004, 407 patients with FIGO Stage III (FIGO Stage IIIa in 19 and IIIb in 388) were treated with external beam radiotherapy (RT) and high-dose rate brachytherapy.
  • RESULTS: The complete response rate was 79.6%, and the 5-year overall survival rates for Stage IIIa and Stage IIIb carcinoma of the cervix were 82.1% and 54.8%, respectively.
  • To determine which parameters of tumor extent had an influence on prognosis for Stage IIIb patients, pelvic wall (PW) extension and hydronephrosis (HD) retained significance on multivariate analysis.
  • Stage IIIb patients were divided into three subgroups according to PW extension and HD: low risk (unilateral PW extension without HD), intermediate risk (HD without PW extension or bilateral PW extension without HD), and high risk (unilateral or bilateral PW extension with HD).
  • CONCLUSIONS: FIGO Stage III carcinoma of the cervix covers considerably heterogeneous subgroups according to tumor extent.
  • Before initiation of treatment, we suggest that physicians determine a tailored treatment policy based on tumor heterogeneity for each Stage III patient.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Brachytherapy / methods. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Chi-Square Distribution. Female. Humans. Middle Aged. Survival Rate. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1605-6; author reply 1606-7 [20637983.001]
  • (PMID = 19467800.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Babel N, Gabdrakhmanova L, Hammer MH, Schoenemann C, Skrypnikov V, Poliak N, Volk HD, Reinke P: Predictive value of cytokine gene polymorphisms for the development of end-stage renal disease. J Nephrol; 2006 Nov-Dec;19(6):802-7
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of cytokine gene polymorphisms for the development of end-stage renal disease.
  • Since TNF-alfa and IL-10 are involved in regulation of inflammation, and TGF-beta 1 can induce fibrosis and renal insufficiency - dominant features of end-stage renal disease (ESRD), we explored the hypothesis that polymorphisms of these cytokine genes may be possible genetic susceptibility factors for the progression of renal failure.
  • Statistical analysis of genotype frequencies made separately for the underlying renal disease (diabetes or glomerulo-nephritis) revealed the same linkage trend: TGF-beta 1 (codon 10) TT and IL-10 (-1082) GG were associated with type 2 diabetic nephropathy (p<0.001 and p<0.05, respectively) and chronic glomerulonephritis (p<0.001 and p<0.01, respectively).
  • [MeSH-minor] Adult. Aged. Female. Germany. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Diabetic Kidney Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173255.001).
  • [ISSN] 1121-8428
  • [Journal-full-title] Journal of nephrology
  • [ISO-abbreviation] J. Nephrol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


33. Berger A, Edelsberg J, Inglese GW, Bhattacharyya SK, Oster G: Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease. Am J Manag Care; 2009 Aug;15(8):509-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
  • OBJECTIVE: To compare healthcare utilization and costs in patients with end-stage renal disease (ESRD) beginning peritoneal dialysis (PD) or hemodialysis (HD).
  • Patients were designated as PD patients or as HD patients based on first-noted treatment.
  • The PD patients were matched to HD patients using propensity scoring to control for differences in pretreatment characteristics.
  • Healthcare utilization and costs were then compared over 12 months between propensity-matched PD patients and HD patients using paired t tests and Wilcoxon signed rank tests for continuous variables and using Bowker and McNemar tests for categorical variables, as appropriate.
  • RESULTS: A total of 463 patients met all study entrance criteria; 56 (12%) began treatment with PD, and 407 (88%) began treatment with HD.
  • Fifty PD patients could be propensity matched to an equal number of HD patients.
  • The HD patients were more than twice as likely as matched PD patients to be hospitalized over the subsequent 12 months (hazard ratio, 2.17; 95% confidence interval, 1.34-3.51; P <.01).
  • CONCLUSIONS: Among patients with ESRD, PD patients are less likely than HD patients to be hospitalized in the year following initiation of dialysis.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Comorbidity. Female. Health Care Costs / statistics & numerical data. Humans. Insurance Claim Review. Logistic Models. Male. Middle Aged. Peritoneal Dialysis / economics. Prevalence. Proportional Hazards Models. Retrospective Studies. United States / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670954.001).
  • [ISSN] 1936-2692
  • [Journal-full-title] The American journal of managed care
  • [ISO-abbreviation] Am J Manag Care
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Ge RS, Dong Q, Sottas CM, Chen H, Zirkin BR, Hardy MP: Gene expression in rat leydig cells during development from the progenitor to adult stage: a cluster analysis. Biol Reprod; 2005 Jun;72(6):1405-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression in rat leydig cells during development from the progenitor to adult stage: a cluster analysis.
  • The postnatal development of Leydig cells can be divided into three distinct stages: initially they exist as fibroblast-like progenitor Leydig cells (PLCs) appearing in the testis by Days 14-21; subsequently, by Day 35, they become immature Leydig cells (ILCs) acquiring steroidogenic organelle structure and enzyme activities but metabolizing most of the testosterone they produce; finally, as adult Leydig cells (ALCs) by Day 90, they actively produce testosterone.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15716394.001).
  • [ISSN] 0006-3363
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD-32588
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Glucocorticoid; 0 / Receptors, Mineralocorticoid; 3XMK78S47O / Testosterone; EC 1.1.1.146 / 11-beta-Hydroxysteroid Dehydrogenase Type 2
  •  go-up   go-down


35. Bloom SL, Casey BM, Schaffer JI, McIntire DD, Leveno KJ: A randomized trial of coached versus uncoached maternal pushing during the second stage of labor. Am J Obstet Gynecol; 2006 Jan;194(1):10-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of coached versus uncoached maternal pushing during the second stage of labor.
  • OBJECTIVE: The objective of this study was to compare obstetrical outcomes associated with coached versus uncoached pushing during the second stage of labor.
  • STUDY DESIGN: Upon reaching the second stage, previously consented nulliparous women with uncomplicated labors and without epidural analgesia were randomly assigned to coached (n = 163) versus uncoached (n = 157) pushing.
  • RESULTS: The second stage of labor was abbreviated by approximately 13 minutes in coached women (P = .01).
  • CONCLUSION: Although associated with a slightly shorter second stage, coached maternal pushing confers no other advantages and withholding such coaching is not harmful.
  • [MeSH-major] Delivery, Obstetric / methods. Labor Stage, Second. Midwifery
  • [MeSH-minor] Adult. Female. Humans. Natural Childbirth. Pregnancy. Time Factors. Unnecessary Procedures

  • MedlinePlus Health Information. consumer health - Childbirth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2007 Jan;196(1):e34; author reply e34 [16824471.001]
  • [CommentIn] Am J Obstet Gynecol. 2006 Dec;195(6):e5; author reply e6 [16584703.001]
  • (PMID = 16389004.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01-HD-38663
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


36. Hou S, Chen Y, Liang J, Li L, Wu T, Tian XC, Zhang S: Developmental stage-specific imprinting of IPL in domestic pigs (Sus scrofa). J Biomed Biotechnol; 2010;2010:527539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developmental stage-specific imprinting of IPL in domestic pigs (Sus scrofa).
  • For example, it is imprinted in 1-day old newborns (expressed from the maternal allele), but imprinting was lost in 180-day-old adult (expressed from both parental alleles).
  • The expression level was significantly higher in spleen, duodenum, lung, and bladder of 180-day-old Lantang adult compared to that in 1-day-old newborns Lantang pigs (P < .05).
  • In conclusion, the imprinting of the porcine IPL gene is developmental stage and tissue specific.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Mar 22;9(5):757-63 [10749982.001]
  • [Cites] Epigenetics. 2009 May 16;4(4):235-40 [19483473.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1086-9 [11498578.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7490-5 [12032310.001]
  • [Cites] Mamm Genome. 2002 Jul;13(7):388-98 [12140686.001]
  • [Cites] Gene. 2002 Nov 13;301(1-2):67-77 [12490325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1056-61 [12552136.001]
  • [Cites] Mech Dev. 2004 Oct;121(10):1199-210 [15327781.001]
  • [Cites] Biol Reprod. 2004 Nov;71(5):1540-4 [15240429.001]
  • [Cites] DNA. 1987 Aug;6(4):283-95 [3652904.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(8):2766-70 [2565038.001]
  • [Cites] Diagn Mol Pathol. 1995 Dec;4(4):249-55 [8634780.001]
  • [Cites] Hum Mol Genet. 1997 Nov;6(12):2021-9 [9328465.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1052-6 [9500470.001]
  • [Cites] Curr Top Dev Biol. 1999;43:1-49 [9891882.001]
  • [Cites] Mol Reprod Dev. 2005 Aug;71(4):431-8 [15895469.001]
  • [Cites] Placenta. 2006 Jun-Jul;27(6-7):540-9 [16125225.001]
  • [Cites] J Reprod Med. 2006 Nov;51(11):861-7 [17165430.001]
  • [Cites] Physiol Genomics. 2007 May 11;29(3):267-79 [17264241.001]
  • [Cites] BMC Mol Biol. 2007;8:67 [17697375.001]
  • [Cites] Exp Mol Pathol. 2008 Jun;84(3):234-9 [18501891.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7947-50 [10859367.001]
  • (PMID = 20589073.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD40889
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / TSSC3 protein
  • [Other-IDs] NLM/ PMC2879551
  •  go-up   go-down


37. Kim SH, Choi YM, Chae HD, Kim CH, Kang BM: Decreased expression of angiogenin in the eutopic endometrium from women with advanced stage endometriosis. J Korean Med Sci; 2008 Oct;23(5):802-7
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of angiogenin in the eutopic endometrium from women with advanced stage endometriosis.
  • Thirty-two women with advanced stage endometriosis and 29 control women were recruited.
  • These findings suggest that the relative deficiency of angiogenin expression in the secretory endometrium could impair implantation in women with advanced stage endometriosis.
  • [MeSH-minor] Adult. Female. Fertility. Humans. Immunohistochemistry / methods. Menstrual Cycle. Models, Biological. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5609-14 [11701742.001]
  • [Cites] Hum Reprod Update. 1998 Sep-Oct;4(5):736-40 [10027628.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6023-8 [11972026.001]
  • [Cites] Hum Reprod. 2000 Aug;15 Suppl 3:67-77 [11041223.001]
  • [Cites] Placenta. 2001 Jan;22(1):1-13 [11162347.001]
  • [Cites] Endocrinology. 2003 Jul;144(7):2870-81 [12810542.001]
  • [Cites] Am J Reprod Immunol. 2004 Feb;51(2):166-73 [14748845.001]
  • [Cites] Fertil Steril. 2004 Jul;82(1):93-6 [15236995.001]
  • [Cites] Am J Obstet Gynecol. 1975 May;122(2):262-3 [1155504.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Aug;79(2):643-9 [7519194.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3112-8 [8768883.001]
  • [Cites] Biol Reprod. 1997 Jun;56(6):1390-9 [9166690.001]
  • [Cites] Mol Hum Reprod. 1996 Jan;2(1):40-5 [9238656.001]
  • [Cites] Fertil Steril. 1997 Oct;68(4):585-96 [9341595.001]
  • [Cites] Cell Mol Life Sci. 1998 Aug;54(8):811-24 [9760990.001]
  • [Cites] Ann N Y Acad Sci. 2002 Mar;955:252-64; discussion 293-5, 396-406 [11949953.001]
  • (PMID = 18955785.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.1.27.- / angiogenin; EC 3.1.27.5 / Ribonuclease, Pancreatic
  • [Other-IDs] NLM/ PMC2579997
  •  go-up   go-down


38. Lamm BM, Gottlieb HD, Paley D: A two-stage percutaneous approach to charcot diabetic foot reconstruction. J Foot Ankle Surg; 2010 Nov-Dec;49(6):517-22
MedlinePlus Health Information. consumer health - Diabetic Foot.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-stage percutaneous approach to charcot diabetic foot reconstruction.
  • Feet were operated on at various stages of Charcot deformity: Eichenholtz stage I (1 foot), Eichenholtz stage II (6 feet), and Eichenholtz stage III (4 feet).
  • [MeSH-minor] Achilles Tendon / surgery. Adult. Aged. Equinus Deformity / surgery. Female. Fluoroscopy. Foot Bones / surgery. Foot Joints / radiography. Foot Joints / surgery. Humans. Male. Middle Aged. Muscle, Skeletal / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20864361.001).
  • [ISSN] 1542-2224
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Hada R, Khakurel S, Agrawal RK, Kafle RK, Bajracharya SB, Raut KB: Incidence of end stage renal disease on renal replacement therapy in Nepal. Kathmandu Univ Med J (KUMJ); 2009 Jul-Sep;7(27):301-5
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of end stage renal disease on renal replacement therapy in Nepal.
  • BACKGROUND: End stage renal disease patients are treated with dialysis in Nepal.
  • But there is no renal registry to indicate the burden of disease in the country.
  • The haemodialysis (HD) registry, HD patients file, intermittent peritoneal dialysis (IPD) registry of Bir Hospital, Shree Birendra Hospital, Tribhuwan University Teaching hospital and National Kidney Center were reviewed.
  • Initial mode of RRT was IPD in 58.2%, HD in 41.7% and pre-emptive transplantation in 0.1% patients.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Nepal / epidemiology. Prognosis. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071881.001).
  • [ISSN] 1812-2078
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Nepal
  •  go-up   go-down


40. Bozbas SS, Akcay S, Altin C, Bozbas H, Karacaglar E, Kanyilmaz S, Sayin B, Muderrisoglu H, Haberal M: Pulmonary hypertension in patients with end-stage renal disease undergoing renal transplantation. Transplant Proc; 2009 Sep;41(7):2753-6
MedlinePlus Health Information. consumer health - Pulmonary Hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary hypertension in patients with end-stage renal disease undergoing renal transplantation.
  • INTRODUCTION: Pulmonary hypertension (PHT) has been reported to occur in a considerable proportion of patients with end-stage renal disease (ESRD).
  • PATIENTS AND METHODS: We retrospectively evaluated the records, clinical and demographic data as well as laboratory results of 500 adult patients who underwent renal transplantation at our institution.
  • The mean duration of dialysis was 40 months; 432 patients (86.4%) were on hemodialysis (HD) and 68 (13.6%) on peritoneal dialysis (PD).
  • Concerning the type of dialysis, the ratio of patients having PHT was higher in the HD compared with the PD group (18.8% vs 5.9%; P = .008).
  • The prevalence of chronic obstructive pulmonary artery disease, asthma, smoking, hypertension, and diabetes mellitus did not differ between patients with versus without PHT (P > .05 for all).
  • The time on renal replacement therapy particularly HD as the treatment was associated with greater prevalences.
  • [MeSH-minor] Adult. Diabetes Mellitus / epidemiology. Diabetic Nephropathies / surgery. Echocardiography, Doppler. Female. Humans. Male. Middle Aged. Peritoneal Dialysis. Prognosis. Pulmonary Artery / physiology. Pulmonary Artery / physiopathology. Pulmonary Disease, Chronic Obstructive / epidemiology. Renal Dialysis. Retrospective Studies. Young Adult


41. Teerawattananon Y, Mugford M, Tangcharoensathien V: Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health; 2007 Jan-Feb;10(1):61-72
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
  • OBJECTIVE: To examine the value for money of including peritoneal dialysis (PD) or hemodialysis (HD) into the universal health insurance scheme of Thailand.
  • METHODS: A probabilistic Markov model applied to end-stage renal disease (ESRD) patients aged 20 to 70 years was developed to examine the incremental cost-effectiveness ratio (ICER) of palliative care versus 1) providing PD as an initial treatment followed by HD if complications/switching occur; and 2) providing HD followed by PD if complications/switching occur.
  • RESULTS: Using a societal perspective, the average ICER of initial treatment with PD and the average ICER of initial treatment with HD were 672,000 and 806,000 Baht per quality-adjusted life-year (QALY) gained (52,000 and 63,000 purchasing power parity [PPP] US$/QALY) compared with palliative care.
  • CONCLUSIONS: The results suggest that offering PD as initial treatment was a better choice than offering HD, but it would only be considered a cost-effective strategy if the social willingness-to-pay threshold was at or higher than 700,000 Baht per QALY (54,000 PPP US$/QALY) for the age 20 group and 750,000 Baht per QALY (58,000 PPP US$/QALY) for age 70 years.
  • [MeSH-minor] Adult. Aged. Cost-Benefit Analysis. Humans. Markov Chains. Middle Aged. Models, Econometric. National Health Programs / economics. Proportional Hazards Models. Quality-Adjusted Life Years. Survival Analysis. Thailand. Universal Coverage

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17261117.001).
  • [ISSN] 1098-3015
  • [Journal-full-title] Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • [ISO-abbreviation] Value Health
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. O'Connell JM, Novins DK, Beals J, Whitesell N, Libby AM, Orton HD, Croy CD, AI-SUPERPFP Team: Childhood characteristics associated with stage of substance use of American Indians: Family background, traumatic experiences, and childhood behaviors. Addict Behav; 2007 Dec;32(12):3142-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood characteristics associated with stage of substance use of American Indians: Family background, traumatic experiences, and childhood behaviors.
  • The purpose of this analysis is to examine childhood characteristics associated with stage of substance use in adulthood in two American Indian (AI) populations.
  • We used descriptive and multivariate analysis to examine correlates of four mutually exclusive stages of substance use: lifetime abstinence (Stage 0), use of alcohol only (Stage 1A), use of marijuana/inhalants with or without alcohol (Stage 1B), and use of other illicit drugs with or without the previously listed substances (Stage 2).
  • Problematic substance use by parents, younger age of first substance use, initiating substance use with a drug (with or without alcohol), and adolescent conduct problems were associated with higher stage substance use.
  • Persons who experienced sexual abuse, witnessed family violence, or experienced other traumatic events before the age of 18 were more likely to be at Stage 1B than Stage 1A.

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Drugs and Young People.
  • MedlinePlus Health Information. consumer health - Native American Health.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2001 Oct;40(10):1168-74 [11589529.001]
  • [Cites] Cult Med Psychiatry. 2003 Sep;27(3):259-89 [14510095.001]
  • [Cites] J Stud Alcohol. 2004 Jan;65(1):74-83 [15000506.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2004 Mar;43(3):316-24 [15076265.001]
  • [Cites] Science. 1975 Nov 28;190(4217):912-4 [1188374.001]
  • [Cites] Addiction. 2006 Jan;101(1):69-83 [16393193.001]
  • [Cites] Am J Public Health. 1996 Nov;86(11):1594-8 [8916526.001]
  • [Cites] Psychol Med. 1997 Sep;27(5):1101-19 [9300515.001]
  • [Cites] Am J Public Health. 2005 May;95(5):851-9 [15855465.001]
  • [Cites] Am J Psychiatry. 2005 Sep;162(9):1723-32 [16135633.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2005 Dec;44(12):1230-40 [16292114.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 1992;5(1):13-31 [1420537.001]
  • (PMID = 17804171.001).
  • [ISSN] 0306-4603
  • [Journal-full-title] Addictive behaviors
  • [ISO-abbreviation] Addict Behav
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH048174-05; United States / NIMH NIH HHS / MH / P01 MH042473; United States / NIMH NIH HHS / MH / P01 MH042473-20; United States / NIAAA NIH HHS / AA / AA013800-01; United States / NIMH NIH HHS / MH / MH048174-05; United States / NIMH NIH HHS / MH / R01 MH48174; United States / NIMH NIH HHS / MH / P01 MH42473; United States / NIAAA NIH HHS / AA / R01 AA013800; United States / NIDA NIH HHS / DA / R01 DA14817; United States / NIAAA NIH HHS / AA / R01 AA013800-01; United States / NIAAA NIH HHS / AA / R01 AA13800; United States / NIDA NIH HHS / DA / R01 DA014817
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS32661; NLM/ PMC2447861
  •  go-up   go-down


43. Lee SW, Park GH, Lee SW, Um WH, Kwon SH, Song JH, Kim MJ: Different pattern of fluid loss from the lower extremities in normohydrated and overhydrated stage 5 chronic-kidney-disease patients after haemodialysis. Nephrology (Carlton); 2008 Apr;13(2):109-15
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different pattern of fluid loss from the lower extremities in normohydrated and overhydrated stage 5 chronic-kidney-disease patients after haemodialysis.
  • AIM: It is unclear whether fluid is lost from each body segment in a similar manner during haemodialysis (HD) in normohydrated (NH) and overhydrated (OH) patients.
  • METHODS: The authors measured changes in regional-body fluid compartments using segmental multifrequency bioelectrical impedance analysis before and after HD in 26 stage 5 chronic-kidney-disease patients.
  • [MeSH-minor] Adult. Aged. Body Composition. Body Water / metabolism. Body Weight. Cross-Sectional Studies. Electric Impedance. Extracellular Fluid / metabolism. Female. Humans. Lower Extremity. Male. Middle Aged. Models, Biological. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Fluid and Electrolyte Balance.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275498.001).
  • [ISSN] 1440-1797
  • [Journal-full-title] Nephrology (Carlton, Vic.)
  • [ISO-abbreviation] Nephrology (Carlton)
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


44. Kim Y, Evangelista LS, Phillips LR, Pavlish C, Kopple JD: The End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ): testing the psychometric properties in patients receiving in-center hemodialysis. Nephrol Nurs J; 2010 Jul-Aug;37(4):377-93
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ): testing the psychometric properties in patients receiving in-center hemodialysis.
  • Reported treatment adherence rates of patients with end stage renal disease (ESRD) have been extremely varied due to lack of reliable and valid measurement tools.
  • This study was conducted to develop and test an instrument to measure treatment adherence to hemodialysis (HD) attendance, medications, fluid restrictions, and diet prescription among patients with ESRD.
  • This article describes the methodological approach used to develop and test the psychometric properties (such as reliability and validity) of the 46-item ESRD-Adherence Questionnaire (ESRD-AQ) in a cohort of patients receiving maintenance HD at dialysis centers in Los Angeles County.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nurs Res. 1986 Nov-Dec;35(6):382-5 [3640358.001]
  • [Cites] ANNA J. 1988 Apr;15(2):96-100 [3369901.001]
  • [Cites] ANNA J. 1989 Jun;16(4):278-82, 285, discussion 286 [2742396.001]
  • [Cites] Soc Sci Med. 1993 Oct;37(8):1035-43 [8235736.001]
  • [Cites] Am J Kidney Dis. 1994 Dec;24(6):921-3 [7985669.001]
  • [Cites] J Consult Clin Psychol. 1995 Jun;63(3):454-9 [7608358.001]
  • [Cites] J Am Diet Assoc. 1995 Nov;95(11):1301-6 [7594127.001]
  • [Cites] Kaohsiung J Med Sci. 1997 Apr;13(4):243-54 [9177086.001]
  • [Cites] Am J Kidney Dis. 1998 Apr;31(4):607-17 [9531176.001]
  • [Cites] Med Care. 1982 Jun;20(6):567-80 [7109740.001]
  • [Cites] J Am Soc Nephrol. 2004 Aug;15(8):2208-18 [15284307.001]
  • [Cites] J Am Diet Assoc. 2004 Jan;104(1):35-41 [14702581.001]
  • [Cites] Nephrol Dial Transplant. 2004 Jan;19(1):100-7 [14671045.001]
  • [Cites] Nephrol Dial Transplant. 2003 Aug;18(8):1585-91 [12897099.001]
  • [Cites] Kidney Int. 2003 Jul;64(1):254-62 [12787417.001]
  • [Cites] Nephrol Nurs J. 2003 Apr;30(2):209-17; discussion 218 [12736999.001]
  • [Cites] Res Nurs Health. 2003 Apr;26(2):143-52 [12652610.001]
  • [Cites] Am J Manag Care. 2003 Feb;9(2):155-71 [12597603.001]
  • [Cites] Int J Nurs Stud. 2002 Sep;39(7):695-704 [12231026.001]
  • [Cites] Ren Fail. 2002 Jan;24(1):37-48 [11921697.001]
  • [Cites] Nurs Res. 2002 Jan-Feb;51(1):59-62 [11822570.001]
  • [Cites] J Clin Nurs. 2001 Sep;10(5):707-15 [11822521.001]
  • [Cites] Nephrol Dial Transplant. 2002 Jan;17(1):93-9 [11773470.001]
  • [Cites] Nephrol Nurs J. 2000 Jun;27(3):299-304 [11249328.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 Feb;37(2):232-8 [18993090.001]
  • [Cites] Cancer Invest. 2008 Jun;26(5):504-10 [18568773.001]
  • [Cites] Nurs Res. 2007 Sep-Oct;56(5):361-6 [17846558.001]
  • [Cites] Am J Kidney Dis. 1998 Jul;32(1):139-45 [9669435.001]
  • [Cites] Am J Crit Care. 2007 May;16(3):222-35; quiz 236 [17460313.001]
  • [Cites] Res Nurs Health. 2006 Oct;29(5):489-97 [16977646.001]
  • [Cites] Kidney Int Suppl. 2005 Jan;(93):S63-8 [15613071.001]
  • [Cites] JAMA. 1999 Apr 7;281(13):1211-3 [10199431.001]
  • [Cites] Res Nurs Health. 2007 Aug;30(4):459-67 [17654487.001]
  • (PMID = 20830945.001).
  • [ISSN] 1526-744X
  • [Journal-full-title] Nephrology nursing journal : journal of the American Nephrology Nurses' Association
  • [ISO-abbreviation] Nephrol Nurs J
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL093466-01; United States / NHLBI NIH HHS / HL / R01 HL093466-02; United States / NHLBI NIH HHS / HL / R01 HL093466-01; None / None / / P30 AG021684-10; United States / NHLBI NIH HHS / HL / 1R01HL093466-01; United States / NIA NIH HHS / AG / P30 AG021684; United States / NHLBI NIH HHS / HL / R01 HL093466-03; United States / NIA NIH HHS / AG / P30 AG021684-10; United States / NHLBI NIH HHS / HL / R01 HL093466; United States / NIA NIH HHS / AG / P30-AG02-1684
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS258802; NLM/ PMC3077091
  •  go-up   go-down


45. Macdonald JA, McDonald SP, Hawley CM, Rosman J, Brown F, Wiggins KJ, Bannister K, Johnson DW: Recovery of renal function in end-stage renal failure--comparison between peritoneal dialysis and haemodialysis. Nephrol Dial Transplant; 2009 Sep;24(9):2825-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recovery of renal function in end-stage renal failure--comparison between peritoneal dialysis and haemodialysis.
  • METHODS: The study reviewed all patients in Australia and New Zealand who commenced dialysis for treatment of end-stage renal disease (ESRD) between 1963 and 2006.
  • RESULTS: During the study period, 15 912 individuals received peritoneal dialysis (PD) and 23 658 received haemodialysis (HD).
  • Renal recovery occurred in 176 (1.1%) PD and 244 (1.0%) HD patients.
  • Recovery was significantly more likely in patients with higher baseline eGFR, with no hypertension or peripheral vascular disease, and with certain causes of kidney failure (autoimmune renal disease, haemolytic uraemic syndrome, interstitial nephritis, obstructive uropathy, paraproteinaemia and renovascular nephrosclerosis).
  • Recovery was less likely in Maori/Pacific Islanders and polycystic kidney disease.
  • [MeSH-minor] Adult. Aged. Australia. Cohort Studies. Female. Humans. Male. Middle Aged. New Zealand. Proportional Hazards Models. Registries. Time Factors

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443649.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Gultekin B, Ozkan S, Uguz E, Atalay H, Akay T, Arslan A, Sezgin A, Ozdemir N, Tasdelen A, Aslamaci S: Valve replacement surgery in patients with end-stage renal disease: long-term results. Artif Organs; 2005 Dec;29(12):972-5
Hazardous Substances Data Bank. WARFARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valve replacement surgery in patients with end-stage renal disease: long-term results.
  • METHODS: From 1994 to 2001, 29 end-stage renal disease (ESRD) patients on hemodialysis (HD) program underwent 30 valve replacement operations: 29 received mechanical valves (97%), and one received bioprosthetic valves.
  • HD program was discontinued for two patients after renal transplantation in the follow-up period.
  • CONCLUSIONS: Life quality is better and life expectancy is longer after valve replacement in ESRD patients who have valvular disease.
  • [MeSH-minor] Adolescent. Adult. Aged. Anticoagulants / therapeutic use. Bioprosthesis. Female. Follow-Up Studies. Humans. Kidney Transplantation. Life Expectancy. Male. Middle Aged. Renal Dialysis. Treatment Outcome. Warfarin / therapeutic use

  • MedlinePlus Health Information. consumer health - Heart Valve Diseases.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16305653.001).
  • [ISSN] 0160-564X
  • [Journal-full-title] Artificial organs
  • [ISO-abbreviation] Artif Organs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 5Q7ZVV76EI / Warfarin
  •  go-up   go-down


47. Rouse DJ, Weiner SJ, Bloom SL, Varner MW, Spong CY, Ramin SM, Caritis SN, Peaceman AM, Sorokin Y, Sciscione A, Carpenter MW, Mercer BM, Thorp JM Jr, Malone FD, Harper M, Iams JD, Anderson GD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network: Second-stage labor duration in nulliparous women: relationship to maternal and perinatal outcomes. Am J Obstet Gynecol; 2009 Oct;201(4):357.e1-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-stage labor duration in nulliparous women: relationship to maternal and perinatal outcomes.
  • OBJECTIVE: The purpose of this study was to assess maternal and perinatal outcomes as a function of second-stage labor duration.
  • RESULTS: Of 5341 participants, 4126 women reached the second stage of labor.
  • As the duration of the second stage increased, spontaneous vaginal delivery rates declined, from 85% when the duration was <1 hour to 9% when it was > or =5 hours.
  • Adverse maternal outcomes that were associated significantly with the duration of the second stage of labor included chorioamnionitis (overall rate, 3.9%), third- or fourth-degree perineal laceration (overall rate, 8.7%), and uterine atony (overall rate, 3.9%).
  • Odds ratios for each additional hour of the second stage of labor ranged from 1.3-1.8.
  • Among individual adverse neonatal outcomes, only admission to a neonatal intensive care unit was associated significantly with second stage duration (odds ratio, 1.4).
  • CONCLUSION: The second stage of labor does not need to be terminated for duration alone.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Obstet Gynecol Scand. 2002 Mar;81(3):214-21 [11966477.001]
  • [Cites] J Obstet Gynaecol. 2003 May;23(3):255-7 [12850854.001]
  • [Cites] Obstet Gynecol. 2003 Jul;102(1):52-8 [12850607.001]
  • [Cites] Am J Obstet Gynecol. 2004 Sep;191(3):933-8 [15467567.001]
  • [Cites] Obstet Gynecol. 1977 Mar;49(3):266-9 [300151.001]
  • [Cites] J Reprod Med. 1990 Mar;35(3):229-31 [2325032.001]
  • [Cites] Br J Obstet Gynaecol. 1992 May;99(5):381-5 [1622909.001]
  • [Cites] Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):906-12 [7573267.001]
  • [Cites] JAMA. 1996 Nov 13;276(18):1480-6 [8903259.001]
  • [Cites] N Engl J Med. 2006 Nov 23;355(21):2195-202 [17124017.001]
  • [CommentOn] Am J Obstet Gynecol. 2009 Oct;201(4):337-8 [19788964.001]
  • (PMID = 19788967.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD36801; United States / NICHD NIH HHS / HD / U10 HD040500; United States / NICHD NIH HHS / HD / UG1 HD027869; United States / NICHD NIH HHS / HD / U10 HD040544; United States / NICHD NIH HHS / HD / HD027869-19; United States / NICHD NIH HHS / HD / UG1 HD034116; United States / NICHD NIH HHS / HD / HD27869; United States / NICHD NIH HHS / HD / HD34136; United States / NICHD NIH HHS / HD / UG1 HD040560; United States / NICHD NIH HHS / HD / U10 HD034136; United States / NICHD NIH HHS / HD / HD27860; United States / NICHD NIH HHS / HD / UG1 HD027915; United States / NICHD NIH HHS / HD / U10 HD040485; United States / NICHD NIH HHS / HD / HD40512; United States / NICHD NIH HHS / HD / UG1 HD040544; United States / NICHD NIH HHS / HD / UG1 HD034208; United States / NICHD NIH HHS / HD / UG1 HD040512; United States / NICHD NIH HHS / HD / HD40545; United States / NICHD NIH HHS / HD / U10 HD034116; United States / NICHD NIH HHS / HD / HD40485; United States / NICHD NIH HHS / HD / HD40560; United States / NICHD NIH HHS / HD / HD21410; United States / NICHD NIH HHS / HD / U10 HD027869; United States / NICHD NIH HHS / HD / U10 HD027917; United States / NICHD NIH HHS / HD / HD34116; United States / NICHD NIH HHS / HD / U10 HD027915; United States / NICHD NIH HHS / HD / UG1 HD040545; United States / NICHD NIH HHS / HD / UG1 HD040485; United States / NICHD NIH HHS / HD / U10 HD027860; United States / NICHD NIH HHS / HD / HD40500; United States / NICHD NIH HHS / HD / U10 HD040560; United States / NICHD NIH HHS / HD / U10 HD034208; United States / NICHD NIH HHS / HD / HD34208; United States / NICHD NIH HHS / HD / U10 HD027869-19; United States / NICHD NIH HHS / HD / HD27915; United States / NICHD NIH HHS / HD / UG1 HD040500; United States / NICHD NIH HHS / HD / R24 HD050924; United States / NICHD NIH HHS / HD / U10 HD040512; United States / NICHD NIH HHS / HD / HD27917; United States / NICHD NIH HHS / HD / U10 HD021410; United States / NICHD NIH HHS / HD / U10 HD036801; United States / NICHD NIH HHS / HD / U10 HD040545; United States / NICHD NIH HHS / HD / HD40544; United States / NICHD NIH HHS / HD / U01 HD036801
  • [Publication-type] Comment; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS138529; NLM/ PMC2768280
  • [Investigator] Leveno KJ; Thom E; Northen A; Mclntire D; Nothen A; Bailey K; Grant J; Tate S; Hill-Webb T; Tillinghast J; Allard D; Breault P; Connolly N; Silva J; Milluzzi C; Heggie C; Ehrenberg H; Stetzer B; Pemberton V; Bousleiman S; Husami H; Carmona V; South S; Talucci M; Pollock M; Sherman M; Tocci C; Seltzer E; Brody S; Granados J; Clark K; Mitchell J; Dorman K; Mallett G; Cengic N; Huntley M; Triplett T; Johnson F; Fyffe S; Landon M; Controneo M; Luce M; Birkland H; Bickus M; Creswell-Hartman L; Day MC; Ortiz F; Figueroa B; Shaunfield S; Messer M; McCampbell J; Moseley L; Anderson K; Oshiro B; Porter F; Jolley K; Guzman A; Swain M; Chilton J; Leftwich C; Davido W; Johnson K; Norman G; Steffy B; Sudz C; Blackwell S; Thom EA; Swanson A; Galbis-Reig F; Leuchtenburg L; Pagliaro S; Howell K
  •  go-up   go-down


48. Cheng YW, Hopkins LM, Laros RK Jr, Caughey AB: Duration of the second stage of labor in multiparous women: maternal and neonatal outcomes. Am J Obstet Gynecol; 2007 Jun;196(6):585.e1-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duration of the second stage of labor in multiparous women: maternal and neonatal outcomes.
  • OBJECTIVE: This study was undertaken to examine perinatal outcomes associated with the second stage of labor in multiparous women.
  • Duration of the second stage of labor was stratified into hourly intervals: 0-1 hour, 1-2 hours, 2-3 hours, and 3 hours or longer.
  • RESULTS: Compared with women who delivered between the 0- and 2-hour interval, women with a second stage more than 3 hours had higher risks of operative vaginal deliveries (odds ratio = 13.27; 95% CI [9.38-18.8]), cesarean deliveries (odds ratio = 6.00; [4.06-8.86]), and maternal morbidity including third- or fourth-degree perineal lacerations, postpartum hemorrhage, and chorioamnionitis.
  • CONCLUSION: Multiparous women with a second stage of 3 hours or greater are at increased risks for operative deliveries, peripartum morbidity, and undesirable neonatal outcomes.
  • These outcomes should be considered in the management of multiparous women with a second stage of labor beyond 3 hours.
  • [MeSH-major] Labor Stage, Second. Parity
  • [MeSH-minor] Adult. Apgar Score. California / epidemiology. Cesarean Section / statistics & numerical data. Chorioamnionitis / epidemiology. Cohort Studies. Endometritis / epidemiology. Extraction, Obstetrical / statistics & numerical data. Female. Humans. Hydrogen-Ion Concentration. Infant, Newborn. Intensive Care Units, Neonatal. Length of Stay / statistics & numerical data. Meconium. Multivariate Analysis. Patient Admission / statistics & numerical data. Perineum / injuries. Postpartum Hemorrhage / epidemiology. Pregnancy. Retrospective Studies. Time Factors. Umbilical Arteries / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17547906.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD01262
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


49. Blekher T, Weaver MR, Marshall J, Hui S, Jackson JG, Stout JC, Beristain X, Wojcieszek J, Yee RD, Foroud TM: Visual scanning and cognitive performance in prediagnostic and early-stage Huntington's disease. Mov Disord; 2009 Mar 15;24(4):533-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visual scanning and cognitive performance in prediagnostic and early-stage Huntington's disease.
  • The objective of this study was to evaluate visual scanning strategies in carriers of the Huntington disease (HD) gene expansion and to test whether there is an association between measures of visual scanning and cognitive performance.
  • The study sample included control (NC, n = 23), prediagnostic (PDHD, n = 21), and subjects recently diagnosed with HD (HD, n = 19).
  • There was a significant group effect and a linear trend of decreasing frequency and regularity of visual scanning from NC to PDHD to HD.
  • While all individuals employed a similar visual scanning strategy, the visual scanning measures grew progressively worse from NC to PDHD to HD.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mov Disord. 2000 May;15(3):552-60 [10830423.001]
  • [Cites] Ann Neurol. 2006 Jan;59(1):53-9 [16261565.001]
  • [Cites] Neurology. 2001 Aug 28;57(4):658-62 [11524475.001]
  • [Cites] Neurology. 2002 Mar 12;58(5):695-701 [11889230.001]
  • [Cites] J Clin Exp Neuropsychol. 2002 Apr;24(2):133-45 [11992196.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2003 Winter;15(1):7-16 [12556566.001]
  • [Cites] Biol Psychiatry. 2006 Jan 1;59(1):57-63 [16112655.001]
  • [Cites] Neurology. 2006 Aug 8;67(3):485-7 [16625001.001]
  • [Cites] Neurology. 2006 Aug 8;67(3):394-9 [16855205.001]
  • [Cites] Cogn Behav Neurol. 2006 Dec;19(4):208-16 [17159618.001]
  • [Cites] Neurology. 2003 May 27;60(10):1615-20 [12771251.001]
  • [Cites] Vision Res. 2004 Oct;44(23):2729-36 [15358067.001]
  • [Cites] J Neuropathol Exp Neurol. 1985 Nov;44(6):559-77 [2932539.001]
  • [Cites] Neurology. 1987 Mar;37(3):364-70 [2950337.001]
  • [Cites] Neurology. 1991 Jun;41(6):875-81 [1828547.001]
  • [Cites] J Biochem Biophys Methods. 1992 Dec;25(4):193-205 [1494032.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Ann Neurol. 1995 May;37(5):657-64 [7755361.001]
  • [Cites] Clin Chem. 1996 May;42(5):773-4 [8653908.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] Neurology. 1997 Feb;48(2):394-9 [9040728.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1997 Aug 29;352(1358):1231-9 [9304689.001]
  • [Cites] Vision Res. 1997 Dec;37(24):3639-45 [9425536.001]
  • [Cites] Behav Brain Sci. 1997 Dec;20(4):723-42; discussion 743-67 [10097009.001]
  • [Cites] Arch Neurol. 1999 May;56(5):563-8 [10328251.001]
  • [Cites] Cogn Behav Neurol. 2005 Jun;18(2):102-7 [15970729.001]
  • [Cites] Psychiatry Res. 2005 Oct 30;140(1):55-62 [16199141.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Dec;69(6):773-9 [11080230.001]
  • (PMID = 19053053.001).
  • [ISSN] 1531-8257
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR000750-320784; United States / NINDS NIH HHS / NS / R01 NS042659-05; United States / NINDS NIH HHS / NS / N01-NS-3-2357; United States / NCRR NIH HHS / RR / M01 RR000750; United States / NINDS NIH HHS / NS / R01 NS042659; United States / NCRR NIH HHS / RR / M01 RR000750-320784; United States / NCRR NIH HHS / RR / MO1 RR-00750; United States / NINDS NIH HHS / NS / NS042659-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS171154; NLM/ PMC2834211
  •  go-up   go-down


50. Bristol-Gould SK, Kreeger PK, Selkirk CG, Kilen SM, Mayo KE, Shea LD, Woodruff TK: Fate of the initial follicle pool: empirical and mathematical evidence supporting its sufficiency for adult fertility. Dev Biol; 2006 Oct 1;298(1):149-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fate of the initial follicle pool: empirical and mathematical evidence supporting its sufficiency for adult fertility.
  • The importance of the initial follicle pool in fertility in female adult mammals has recently been debated.
  • Utilizing a mathematical model of the dynamics of follicle progression (primordial to primary to secondary), we examined whether the initial follicle pool is sufficient for adult fertility through reproductive senescence in CD1 mice.
  • Follicles in each stage were counted from postnatal day 6 through 12 months and data were fit to a series of first-order differential equations representing two mechanisms: an initial pool of primordial follicles as the only follicle source (fixed pool model), or an initial primordial follicle pool supplemented by germline stem cells (stem cell model).
  • Our results agree with established dogma that the initial endowment of ovarian follicles is not supplemented by an appreciable number of stem cells; rather, it is sufficient to ensure the fertility needs of the adult mouse.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925987.001).
  • [ISSN] 0012-1606
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / P01 HD021921; United States / NICHD NIH HHS / HD / U54 HD041857; United States / NICHD NIH HHS / HD / HD007068; United States / NICHD NIH HHS / HD / U54 HD41857
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD15
  •  go-up   go-down


51. Yeh CN, Lee WC, Chen MF: Hepatic resection for hepatocellular carcinoma in end-stage renal disease patients: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol; 2005 Apr 14;11(14):2067-71
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for hepatocellular carcinoma in end-stage renal disease patients: two decades of experience at Chang Gung Memorial Hospital.
  • AIM: Hepatocellular carcinoma (HCC) is a common disease in Taiwan.
  • The prevalence of viral hepatitis infection and the subsequent development of HCC are well known to be higher in patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) or peritoneal dialysis (PD) than among the general population.
  • Univariate analysis revealed more associated disease, more physical signs of anemia and postoperative complications, lower hemoglobin, platelet, alpha-fetoprotein, elevated blood urea nitrogen (BUN) and creatinine levels, smaller tumors, lower HBsAg positivity, higher HCV positivity, and longer hospital stays in the ESRD-HCC group compared with the HCC group.
  • Overall and disease-free survival rates were similar between the ESRD-HCC and HCC groups.
  • Comparable overall survival and disease-free survival can be achieved in selected ESRD-HCC patients undergoing hepatic resection when compared with conventional HCC patients.
  • [MeSH-minor] Adult. Aged. Comorbidity. Disease-Free Survival. Female. Humans. Male. Middle Aged. Peritoneal Dialysis. Renal Dialysis. Retrospective Studies. Taiwan

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15810070.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305773
  •  go-up   go-down


52. Turedi S, Cinar O, Yavuz I, Mentese A, Gunduz A, Karahan SC, Topbas M, Cevik E, Yildirim AO, Uzun A, Kaldirim U: Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population. J Nephrol; 2010 May-Jun;23(3):335-40
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population.
  • This study was performed with the primary aim of determining IMA levels in patients with end stage renal disease (ESRD).
  • The secondary aim of the study was to determine the impact of hemodialysis (HD), HD speed, and hemoglobin (Hb) levels on IMA levels.
  • METHODS: The study was conducted with 108 ESRD patients entering HD and 30 healthy volunteers.
  • The serum IMA levels of ESRD patients were compared with the post-HD levels and also with healthy individuals.
  • The interaction between Hb levels and HD treatment and the IMA levels were tested by using the Generalized Linear Model for repeated measurements.
  • RESULTS: The IMA levels of ESRD patients, both pre- and post-HD, were significantly higher than those of the control group.
  • Hb level modifies the effect of HD treatment on IMA concentration in ESRD patients.
  • Furthermore, post-HD levels of IMA were increased at a lower dialysis speed.
  • CONCLUSIONS: Both pre- and post-dialysis IMA levels are higher in ESRD patients entering HD than in healthy individuals.
  • Anemia is an effect-modifier for the effect of HD treatment on IMA levels in ESRD patients.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Renal Dialysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349416.001).
  • [ISSN] 1121-8428
  • [Journal-full-title] Journal of nephrology
  • [ISO-abbreviation] J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Serum Albumin
  •  go-up   go-down


53. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D: N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int; 2007 Mar;71(6):548-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis.
  • In patients with end-stage renal disease (ESRD) in hemodialysis (HD), levels of NT-proBNP are almost always raised.
  • In ESRD patients undergoing HD, we aimed at (i) identifying the factors that affect levels of NT-proBNP, (ii) determining the effect of HD on NT-proBNP, and (iii) determining the prognostic impact of NT-proBNP.
  • Serum NT-proBNP was measured before and after HD (Elecsys 2010).
  • NT-proBNP levels were markedly elevated (pre-HD 4079 pg/ml, post-HD 2759 pg/ml, P<0.001).
  • Patients with higher concentrations, both pre- and post-HD had an increased mortality rate compared to those with lower concentrations (P=0.007, P=0.002).
  • We found age (P=0.009) and NT-proBNP (pre-HD P=0.007, post-HD P=0.001) predictive of death.
  • Our findings demonstrate that CV disease in terms of LVH and reduced LVEF in addition to 24-h urine production and K(t)/V determine NT-proBNP levels.
  • Post-HD levels of NT-proBNP were lower than pre-HD levels; both predictive of mortality.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Cardiovascular Diseases / blood. Cardiovascular Diseases / diagnosis. Cardiovascular Diseases / etiology. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Regression Analysis. Risk Factors. Stroke Volume / physiology. Ventricular Dysfunction, Left / blood. Ventricular Dysfunction, Left / diagnosis. Ventricular Dysfunction, Left / etiology

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Kidney Int. 2007 Mar;71(6):481-3 [17344896.001]
  • (PMID = 17299526.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


54. Matthews C, Catherwood MA, Morris TC, Kettle PJ, Drake MB, Gilmore WS, Alexander HD: Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur J Haematol; 2006 Oct;77(4):309-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
  • This study was designed to investigate associations between TK levels and other prognostic markers, in newly and previously diagnosed Binet stage A patients.
  • Furthermore, the use of serum TK measurement to identify subcategories of disease within those defined by IgV(H) mutational status, gene usage and chromosomal aberrations was investigated.
  • CONCLUSION: A TK level of >8.5 U/L best identified patients with progressive disease.
  • Elevated TK levels could identify patients categorised, at diagnosis, into good prognosis subgroups by the various biological markers (mutated IgV(H), good prognosis chromosomal aberrations, Zap-70(-) and CD38(-)) who subsequently showed disease progression.
  • Additionally, patients with V(H)3-21 gene usage showed high TK levels, irrespective of mutational status, and serum TK measurement retained predictive power as disease progressed in all subcategories studied.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD38 / genetics. Chromosome Aberrations. Disease Progression. Female. Flow Cytometry. Humans. Immunoglobulin Variable Region / genetics. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856923.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunoglobulin Variable Region; EC 2.7.1.21 / Thymidine Kinase; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


55. Norman SA, Localio AR, Zhou L, Weber AL, Coates RJ, Malone KE, Bernstein L, Marchbanks PA, Liff JM, Lee NC, Nadel MR: Benefit of screening mammography in reducing the rate of late-stage breast cancer diagnoses (United States). Cancer Causes Control; 2006 Sep;17(7):921-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefit of screening mammography in reducing the rate of late-stage breast cancer diagnoses (United States).
  • OBJECTIVE: We studied the benefit of modern mammography screening in community settings, evaluating age-related differences in rates of late-stage breast cancer detection.
  • METHODS: Our multicenter population-based case-control study included 931 black and white women with incident breast cancer (American Joint Commission on Cancer Stage IIB or higher) diagnosed 1994-1998 and 4,016 randomly sampled controls never diagnosed with breast cancer.
  • Adjusted odds ratios (ORs) estimated the relative rate of late-stage diagnosis in screened and non-screened women.
  • RESULTS: Women aged 50-64 at diagnosis with at least one screening mammogram in the previous 2 years were significantly less likely to have late-stage diagnosis (OR = 0.41, 95% CI 0.33-0.52).
  • Mammography screening was associated with lower rates of late-stage breast cancer among both premenopausal (OR = 0.64, 95% CI 0.50-0.81) and postmenopausal (OR = 0.44, 95% CI 0.35-0.56) women.
  • CONCLUSIONS: With modern mammography in the community, rates of late-stage breast cancer diagnoses are lower in screened compared to non-screened women ages 40 and older, but age-related differences persist.
  • [MeSH-minor] Adult. Age Distribution. Case-Control Studies. Early Diagnosis. European Continental Ancestry Group. Female. Humans. Middle Aged. Neoplasm Staging. Odds Ratio. Postmenopause. Premenopause. Risk Factors. SEER Program. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16841259.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / PHS HHS / / 200-2002-00370; United States / NCI NIH HHS / CN / N01-CN-0532; United States / NCI NIH HHS / CN / N01-CN-65064; United States / NICHD NIH HHS / HD / N01-HD-2-3166; United States / NICHD NIH HHS / HD / N01-HD-3-3168; United States / NICHD NIH HHS / HD / N01-HD-3-3174; United States / NICHD NIH HHS / HD / N01-HD-3-3175; United States / NICHD NIH HHS / HD / N01-HD-3-3176; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01-PC67006; United States / NICHD NIH HHS / HD / Y01-HD-7022
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


56. Sithinamsuwan P, Niyasom S, Nidhinandana S, Supasyndh O: Dementia and depression in end stage renal disease: comparison between hemodialysis and continuous ambulatory peritoneal dialysis. J Med Assoc Thai; 2005 Nov;88 Suppl 3:S141-7
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dementia and depression in end stage renal disease: comparison between hemodialysis and continuous ambulatory peritoneal dialysis.
  • OBJECTIVES: To determine the prevalence, risk factors of dementia and depression in end stage renal disease (ESRD) who were treated with hemodialysis (HD) compared with those who had continuous ambulatory peritoneal dialysis (CAPD).
  • MATERIAL AND METHOD: A cross-sectional study was conducted on 90 ESRD patients (60 HD and 30 CAPD groups).
  • In the HD group had 8.3% prevalence of dementia and 6.7% of depression, whereas there was 3.3% of dementia and 6.7% of depression in the CAPD group.
  • There was no significance different on prevalence of dementia and depression comparison between the HD and CAPD group.
  • CONCLUSION: Prevalence of dementia and depression in the overall dialysis in ESRD was 6.7% (with 8.3%, 6.7% among the HD group and 3.3%, 6.7% among CAPD group).
  • There was no significant difference on prevalence of dementia and depression comparison between the HD and CAPD group.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Risk Factors

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858952.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


57. Hernandez-Ochoa I, Barnett-Ringgold KR, Dehlinger SL, Gupta RK, Leslie TC, Roby KF, Flaws JA: The ability of the aryl hydrocarbon receptor to regulate ovarian follicle growth and estradiol biosynthesis in mice depends on stage of sexual maturity. Biol Reprod; 2010 Nov;83(5):698-706
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ability of the aryl hydrocarbon receptor to regulate ovarian follicle growth and estradiol biosynthesis in mice depends on stage of sexual maturity.
  • AhrKO follicles from adult mice, however, produced higher androgen levels and expressed higher levels of Ccnd2 compared to WT follicles.
  • Furthermore, AhrKO follicles from adult mice had growth to that of WT follicles.
  • These findings suggest that the AHR regulates follicle growth by altering factors involved in the estradiol biosynthesis pathway as well as key regulators of follicle growth and that this role of AHR depends on stage of sexual maturity.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods. 1999 Nov;19(3):425-33 [10579938.001]
  • [Cites] Mol Endocrinol. 2009 May;23(5):649-61 [19196834.001]
  • [Cites] Toxicol Sci. 2000 Aug;56(2):382-8 [10910997.001]
  • [Cites] Endocrinology. 2001 Jun;142(6):2328-35 [11356679.001]
  • [Cites] Biol Reprod. 2003 May;68(5):1511-7 [12606443.001]
  • [Cites] Anat Embryol (Berl). 2003 Jul;207(1):9-18 [12783319.001]
  • [Cites] Mol Endocrinol. 2004 Sep;18(9):2224-40 [15192076.001]
  • [Cites] Mol Pharmacol. 1973 Nov;9(6):736-47 [4762634.001]
  • [Cites] J Reprod Fertil. 1974 Aug;39(2):411-4 [4415591.001]
  • [Cites] J Reprod Fertil. 1975 Dec;45(3):449-54 [1206644.001]
  • [Cites] J Biol Chem. 1976 Aug 25;251(16):4936-46 [956169.001]
  • [Cites] Biol Reprod. 1982 Sep;27(2):505-16 [6812657.001]
  • [Cites] Mol Cell Endocrinol. 1986 Feb;44(2):141-5 [3005084.001]
  • [Cites] Endocrinology. 1987 May;120(5):1942-50 [3106012.001]
  • [Cites] Mol Endocrinol. 1990 Jan;4(1):22-8 [2325667.001]
  • [Cites] Int Rev Cytol. 1991;124:43-101 [2001918.001]
  • [Cites] Endocrinology. 1991 Sep;129(3):1452-62 [1651851.001]
  • [Cites] Science. 1995 May 5;268(5211):722-6 [7732381.001]
  • [Cites] Pharmacol Ther. 1995;67(2):247-81 [7494865.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6731-6 [8692887.001]
  • [Cites] Nature. 1996 Dec 5;384(6608):470-4 [8945475.001]
  • [Cites] Crit Rev Toxicol. 1997 Mar;27(2):109-34 [9099515.001]
  • [Cites] Vet Pathol. 1997 Nov;34(6):605-14 [9396142.001]
  • [Cites] Mol Endocrinol. 1998 Jul;12(7):924-40 [9658398.001]
  • [Cites] J Reprod Fertil. 1998 May;113(1):27-33 [9713373.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Feb 15;155(1):62-70 [10036219.001]
  • [Cites] Mol Cell Endocrinol. 1999 May 25;151(1-2):57-64 [10411320.001]
  • [Cites] Endocrinology. 1961 Oct;69:851-5 [13787954.001]
  • [Cites] Biol Reprod. 2005 Oct;73(4):825-32 [15972887.001]
  • [Cites] Toxicol Sci. 2005 Nov;88(1):213-21 [16081520.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(22):10040-51 [16260617.001]
  • [Cites] Reprod Biol Endocrinol. 2006;4:16 [16603089.001]
  • [Cites] Am J Primatol. 2007 Jun;69(6):681-91 [17171710.001]
  • [Cites] Biol Reprod. 2007 Jun;76(6):1062-70 [17329597.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Aug 15;223(1):66-72 [17594909.001]
  • [Cites] Biochem Pharmacol. 2009 Feb 15;77(4):547-59 [18977336.001]
  • [Cites] Endocrinology. 2000 Jan;141(1):450-3 [10614669.001]
  • (PMID = 20631400.001).
  • [ISSN] 1529-7268
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / F31 GM072195; United States / NICHD NIH HHS / HD / R01 HD047275; United States / NICHD NIH HHS / HD / R01HD047275
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ahr protein, mouse; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Ccnd2 protein, mouse; 0 / Cyclin D2; 0 / RNA, Messenger; 0 / Receptors, Androgen; 0 / Receptors, Aryl Hydrocarbon; 0 / Receptors, FSH; 0 / Receptors, LH; 0 / Testosterone Congeners; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ PMC2959104
  •  go-up   go-down


58. Yamanaka N, Aoyama T, Ikeda N, Higashihara M, Kamata K: Characteristics of heart rate variability entropy and blood pressure during hemodialysis in patients with end-stage renal disease. Hemodial Int; 2005 Jul;9(3):303-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of heart rate variability entropy and blood pressure during hemodialysis in patients with end-stage renal disease.
  • The aim of this study was to characterize the complexity of HRV in patients with end-stage renal disease (ESRD) and to find a possible clinical utility.
  • Healthy subjects and patients with ESRD undergoing hemodialysis (HD) were recruited.
  • The HD population consisted of patients with and without diabetes mellitus (DM).
  • An electrocardiogram was recorded before HD, and blood pressure was measured during HD.
  • Forty-six healthy subjects and 27 HD patients participated in this study.
  • The ENT negatively correlated with the duration of DM (p = 0.001), systolic blood pressure (p = 0.003), and mean blood pressure (p = 0.004) before a HD session.
  • ENT in HD patients was lower than that in healthy subjects (p < 0.01).
  • ENT in HD patients with DM was lower than that in HD patients without DM (p < 0.01).
  • The change in systolic blood pressure (DeltaSBP) during a HD session showed high correlations to ENT and ultrafiltration rate (UFR) of the dialyzer.
  • ENT also represents a possible prediction of hypotension during a HD session.
  • [MeSH-minor] Adult. Aged. Electrocardiography. Female. Humans. Male. Middle Aged. Ultrafiltration

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16191081.001).
  • [ISSN] 1492-7535
  • [Journal-full-title] Hemodialysis international. International Symposium on Home Hemodialysis
  • [ISO-abbreviation] Hemodial Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


59. Romic Z, Unic A, Derek L, Zivkovic M, Marijancevic D, Kes P, Pehar M: Anti-citrullinated protein antibody and rheumatoid factor in patients with end-stage renal disease. Clin Chem Lab Med; 2009;47(8):959-62
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-citrullinated protein antibody and rheumatoid factor in patients with end-stage renal disease.
  • BACKGROUND: Patients with end-stage renal disease (ESRD) and on hemodialysis (HD) are at increased risk for developing rheumatoid arthritis (RA), as a result of defective immunity.
  • Our aim was to examine if ESRD and the length of HD treatment impact the clinical utility of antibodies to cyclic citrullinated peptides (anti-CCP) and rheumatoid factor (RF) as diagnostic tools for RA.
  • METHODS: We included 94 subjects in our study: 37 healthy volunteers and 57 patients with ESRD who had been undergoing HD for 1-12 years, and without confirmed RA.
  • RESULTS: Our study showed that there is no significant difference between values for anti-CCP (p=0.11) and RF (p=0.98) in control subjects as well as in patients undergoing HD, regardless of the length of time that patients had been undergoing HD treatment.
  • CONCLUSIONS: Our study indicates that HD does not impair the specificity of anti-CCP and RF for RA in patients where the disease has not yet developed.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642861.001).
  • [ISSN] 1437-4331
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Peptides, Cyclic; 0 / cyclic citrullinated peptide; 9009-79-4 / Rheumatoid Factor
  •  go-up   go-down


60. Tarrass F, Benjelloun M, Zamd M, Medkouri G, Hachim K, Benghanem MG, Ramdani B: Heart valve calcifications in patients with end-stage renal disease: analysis for risk factors. Nephrology (Carlton); 2006 Dec;11(6):494-6
Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart valve calcifications in patients with end-stage renal disease: analysis for risk factors.
  • BACKGROUND: The prevalence of valve calcification (VC) in end-stage renal disease patients is high and information regarding risk factors is scarce.
  • Our aims were to determine the prevalence of VC in our maintenance haemodialysis (HD) population and to examine some possible aetiologic factors for its occurrence.
  • METHODS: We studied 90 patients (47 women) on maintenance HD for more than 12 months.
  • CONCLUSION: Findings of the present study are consistent with a role of altered calcium and phosphate metabolism in the pathogenesis of VC in HD patients.
  • [MeSH-minor] Adult. Calcium / blood. Echocardiography. Female. Humans. Male. Middle Aged. Parathyroid Hormone / blood. Phosphorus / blood. Prevalence. Renal Dialysis. Risk Factors

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17199785.001).
  • [ISSN] 1320-5358
  • [Journal-full-title] Nephrology (Carlton, Vic.)
  • [ISO-abbreviation] Nephrology (Carlton)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 27YLU75U4W / Phosphorus; SY7Q814VUP / Calcium
  •  go-up   go-down


61. Chalem Y, Ryckelynck JP, Tuppin P, Verger C, Chauvé S, Glotz D, French Collaborative Group: Access to, and outcome of, renal transplantation according to treatment modality of end-stage renal disease in France. Kidney Int; 2005 Jun;67(6):2448-53
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Access to, and outcome of, renal transplantation according to treatment modality of end-stage renal disease in France.
  • BACKGROUND: Although peritoneal dialysis (PD) is recognized as one of the methods of treatment of end-stage renal disease (ESRD), there have been recurrent concerns about the access of patients treated by this modality to kidney transplantation (KTx), as well as reports showing increased complications of KTx in such patients, such as graft thrombosis and infections.
  • RESULTS: Using a Cox proportional hazard analysis, we found a shorter waiting time for PD patients (RR 0.71, P < 0.0001), which became equivalent to hemodialysis (HD) patients when taking into account the transplant center as a variable (RR 1.0, P= 0.95).
  • [MeSH-minor] Adult. Aged. Female. Graft Survival. Humans. Likelihood Functions. Male. Middle Aged. Peritoneal Dialysis. Proportional Hazards Models. Renal Dialysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882291.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Kim DM, Chung JH, Yoon SH, Kim HL: Effect of fludrocortisone acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis. Nephrol Dial Transplant; 2007 Nov;22(11):3273-6
Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of fludrocortisone acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis.
  • BACKGROUND: Hyperkalaemia is a commonly encountered problem in dialysis patients with end-stage renal disease (ESRD).
  • The aim of the present study was to assess the effect of fludrocortisone acetate (FCA) on reducing serum potassium levels in haemodialysis (HD) patients with hyperkalaemia.
  • METHODS: Prospectively, 21 HD patients with hyperkalaemia were enrolled in this study.
  • CONCLUSIONS: FCA therapy appears to slightly decrease serum potassium value in hyperkalaemic HD patients.
  • Therefore, potentially large-scale studies with increased dose concentrations are needed to minimize the positive potassium balance in hyperkalaemic HD patients.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Sodium-Potassium-Exchanging ATPase / drug effects. Sodium-Potassium-Exchanging ATPase / metabolism. Weight Gain

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Potassium.
  • Hazardous Substances Data Bank. FLUDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17616536.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 514-36-3 / fludrocortisone acetate; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase; RWP5GA015D / Potassium; U0476M545B / Fludrocortisone
  •  go-up   go-down


63. Sui W, Tan J, Guo J, Du G, Dai Y: An altered TH1/TH2 and pro-inflammatory cytokine profile in patients with end-stage renal disease detected by suspension array technology. Ren Fail; 2009;31(1):1-5
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An altered TH1/TH2 and pro-inflammatory cytokine profile in patients with end-stage renal disease detected by suspension array technology.
  • BACKGROUND: Patients with end-stage renal disease (ESRD) have an impaired immune response with a dysregulated Th1/Th2 cytokine network.
  • METHODS: Twelve ESRD patients on HD were enrolled, and their data of cytokines alterations were divided into pre- and post-HD groups, while data from 12 healthy volunteers served as control.
  • RESULTS: In ESRD patients, as compared with controls, the level of IL-10 increased just prior to HD and IL-1beta level decreased only following HD, while the levels of TNF-beta and IL-8 decreased both before and after HD.
  • After HD, the levels of IL-1beta, IL-4, IL-8, and IL-10 in ESRD patients decreased when compared with those before HD.
  • CONCLUSIONS: ESRD patients on HD show an altered cytokine profile with an increase in Th2 cytokine IL-10 and a decrease in Th1 cytokine TNF-beta as well as a reduction in pro-inflammatory cytokine IL-8.
  • HD did affect cytokine profile of ESRD patients, decreasing IL-1, IL-4, IL-8, and IL-10.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Renal Dialysis. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19142802.001).
  • [ISSN] 1525-6049
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


64. Moriyama T, Matsumoto T, Hirakawa K, Ikeda H, Tsuruya K, Hirakata H, Iida M: Helicobacter pylori status and esophagogastroduodenal mucosal lesions in patients with end-stage renal failure on maintenance hemodialysis. J Gastroenterol; 2010 May;45(5):515-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori status and esophagogastroduodenal mucosal lesions in patients with end-stage renal failure on maintenance hemodialysis.
  • OBJECTIVES: The aim of this study was to elucidate the impact of Helicobacter pylori infection on esophagogastroduodenal mucosal lesions in patients with end-stage renal failure on maintenance hemodialysis (HD).
  • METHODS: An upper endoscopy and the (13)C-urea breath test were performed in 198 patients on maintenance HD.
  • RESULTS: The upper endoscopy revealed that gastric erosion was the most frequent (58%) type of esophagogastroduodenal mucosal lesion, followed by duodenal erosion (18%), gastric ulcer (14%), gastroesophageal reflux disease (10%), and duodenal ulcer (7%).
  • The time duration after the introduction of HD was significantly longer and serum pepsinogen I/II ratio was significantly higher in H. pylori-negative patients than in H. pylori-positive patients.
  • CONCLUSIONS: The most common mucosal lesion observed in our study cohort, all of whom were patients on maintenance HD, was gastric erosion.
  • The high prevalence of this type of lesion may be explained partly by the cure of H. pylori infection during the clinical course of maintenance HD.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cohort Studies. Endoscopy, Digestive System. Female. Humans. Male. Middle Aged. Prevalence. Young Adult


65. Peipert J, Redding CA, Blume J, Allsworth JE, Iannuccillo K, Lozowski F, Mayer K, Morokoff PJ, Rossi JS: Design of a stage-matched intervention trial to increase dual method contraceptive use (Project PROTECT). Contemp Clin Trials; 2007 Sep;28(5):626-37
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design of a stage-matched intervention trial to increase dual method contraceptive use (Project PROTECT).
  • This manuscript describes the randomized clinical trial titled Stage-Matched Intervention to Increase Dual Method Use or Project PROTECT.
  • The primary outcomes of this trial were 1) self-reported use of dual methods of contraception and 2) the biological outcomes of an unintended pregnancy or an incident or recurrent sexually transmitted disease.

  • MedlinePlus Health Information. consumer health - Birth Control.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374567.001).
  • [ISSN] 1551-7144
  • [Journal-full-title] Contemporary clinical trials
  • [ISO-abbreviation] Contemp Clin Trials
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD036663; United States / NICHD NIH HHS / HD / 1R01-HD36663-01; United States / NICHD NIH HHS / HD / K24 HD01298-03
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


66. Kim JH, Shin HD, Park BL, Moon MK, Cho YM, Hwang YH, Oh KW, Kim SY, Lee HK, Ahn C, Park KS: SLC12A3 (solute carrier family 12 member [sodium/chloride] 3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy. Diabetes; 2006 Mar;55(3):843-8
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SLC12A3 (solute carrier family 12 member [sodium/chloride] 3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy.
  • Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD).
  • [MeSH-minor] Adult. Aged. Female. Haplotypes. Humans. Male. Middle Aged. Solute Carrier Family 12, Member 3

  • MedlinePlus Health Information. consumer health - Diabetic Kidney Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505253.001).
  • [ISSN] 0012-1797
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Drug; 0 / SLC12A3 protein, human; 0 / Solute Carrier Family 12, Member 3; 0 / Symporters
  •  go-up   go-down


67. Ayazi K, Atabak S, Saghebi R, Ayazi S, Aryasepehr S: Evaluation of efficacy, survival rate and complications of peritoneal catheter placement of patients with end-stage renal disease. Saudi Med J; 2005 Sep;26(9):1391-3
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of efficacy, survival rate and complications of peritoneal catheter placement of patients with end-stage renal disease.
  • OBJECTIVE: Peritoneal dialysis (PD) as an equivalent to hemodialysis (HD) is one renal replacement therapy (RRT), which has several advantages compared to hemodialysis.
  • The purpose of this study is to assess the catheter efficiency, survival rate and complications of PD catheter placement in end-stage renal disease (ESRD) patients.
  • We suggest that more accurate studies on ESRD patients should be carried out to evaluate the use of PD in the primary stage of ESRD instead of HD.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Device Removal. Equipment Contamination. Equipment Failure. Female. Follow-Up Studies. Humans. Iran. Male. Middle Aged. Risk Assessment. Sensitivity and Specificity. Severity of Illness Index. Survival Analysis

  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155654.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


68. Tuzcu A, Bahceci M, Yilmaz ME, Turgut C, Kara IH: The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease. Saudi Med J; 2005 May;26(5):786-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease.
  • OBJECTIVE: To determine the beta-cell function and insulin sensitivity with homeostasis model assessment (HOMA) and area under curve (AUC) in nondiabetic uremic hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) patients cross sectionally.
  • Fifty-one HD patients, 45 CAPD patients, and 50 healthy control subjects were included in the study.
  • Oral glucose tolerance test (OGTT) was performed in the mid-week dialysis-free interval in HD patients, whereas after at least a night without dialysis exchanges in CAPD group.
  • RESULTS: The LDL-cholesterol levels of patients with CAPD was higher than the HD group (p<0.001) and control group (p<0.0001).
  • Baseline insulin levels of CAPD group were higher than the HD group (p<0.001) and the control group (p<0.0001).
  • Area under curve for glucose (AUCgluc) and insulin (AUCins) value of CAPD patients were higher than the HD patients than the control group (p<0.0001).
  • The HOMA [beta-cell function (%B)] values of CAPD group were higher than both HD (p<0.02) and control group (p<0.04).
  • The HOMA [insulin sensitivity (%S)] levels of CAPD group was significantly lower than the HD patients (p<0.002) and the control group (p<0.001).
  • CONCLUSION: The CAPD treatment may lead to insulin insensitivity in non-diabetic end-stage renal disease patients and the high glucose content of CAPD solutions may be responsible for insulin resistance in CAPD patients.
  • [MeSH-minor] Adult. Aged. Area Under Curve. Blood Glucose / metabolism. Female. Glucose Tolerance Test. Humans. Kidney Failure, Chronic / blood. Kidney Failure, Chronic / therapy. Male. Middle Aged. Turkey

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951871.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Dialysis Solutions
  •  go-up   go-down


69. Vaslaki LR, Berta K, Major L, Weber V, Weber C, Wojke R, Passlick-Deetjen J, Falkenhagen D: On-line hemodiafiltration does not induce inflammatory response in end-stage renal disease patients: results from a multicenter cross-over study. Artif Organs; 2005 May;29(5):406-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On-line hemodiafiltration does not induce inflammatory response in end-stage renal disease patients: results from a multicenter cross-over study.
  • BACKGROUND: On-line hemodiafiltration (HDF) represents the supreme blood purification modality for end-stage renal disease (ESRD) patients.
  • As a result, on-line HDF might aggravate chronic inflammation, which correlates with malnutrition, cardiovascular disease, and mortality among ESRD patients.
  • METHODS: In a multicenter cross-over study, 27 ESRD patients were randomly assigned to treatment with on-line HDF and low-flux hemodialysis (HD).
  • Both on-line HDF and low-flux HD were conducted with polysulfone membranes and ultrapure dialysis fluid.
  • Induction of interleukin-1 receptor antagonist (IL-1Ra) and tumor necrosis factor alpha (TNF-alpha) was comparable for on-line HDF and low-flux HD, and there was no intradialytic increase in cytokine production.
  • Similarly, no difference between on-line HDF and low-flux HD was observed for C-reactive protein (CRP) and albumin.
  • [MeSH-minor] Adult. Aged. Albumins / analysis. C-Reactive Protein / analysis. Cross-Over Studies. Cytokines / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Intercellular Adhesion Molecule-1 / blood. Interleukin-1 / blood. Interleukin-6 / blood. Male. Middle Aged. Treatment Outcome. Troponin T / analysis. Tumor Necrosis Factor-alpha / analysis. Vascular Cell Adhesion Molecule-1 / blood

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854217.001).
  • [ISSN] 0160-564X
  • [Journal-full-title] Artificial organs
  • [ISO-abbreviation] Artif Organs
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumins; 0 / Cytokines; 0 / Interleukin-1; 0 / Interleukin-6; 0 / Troponin T; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Cell Adhesion Molecule-1; 126547-89-5 / Intercellular Adhesion Molecule-1; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


70. Atkinson MA, Neu AM, Fivush BA, Frankenfield DL: Disparate outcomes in pediatric peritoneal dialysis patients by gender/race in the End-Stage Renal Disease Clinical Performance Measures project. Pediatr Nephrol; 2008 Aug;23(8):1331-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disparate outcomes in pediatric peritoneal dialysis patients by gender/race in the End-Stage Renal Disease Clinical Performance Measures project.
  • Associations between achievement of adult Kidney Disease Outcomes Quality Initiative (KDOQI) targets for hemoglobin, adequacy and albumin, and race and gender were determined for pediatric peritoneal dialysis patients from the End-Stage Renal Disease (ESRD) Clinical Performance Measures (CPM) project for the period October 2004-March 2005.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483747.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / T32 HD044355
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Serum Albumin
  •  go-up   go-down


71. Cano AE, Neil AK, Kang JY, Barnabas A, Eastwood JB, Nelson SR, Hartley I, Maxwell D: Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis. Am J Gastroenterol; 2007 Sep;102(9):1990-7
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis.
  • OBJECTIVES: The aim of this study was to determine the prevalence of gastrointestinal symptoms in patients with end-stage renal disease undergoing hemodialysis (HD) or peritoneal dialysis (PD) treatment.
  • METHODS: Patients undergoing HD or chronic ambulatory PD in the Department of Renal Medicine of our hospital were asked to complete a locally validated Rome II questionnaire.
  • Patients on HD and their outpatient controls also completed the Hospital Anxiety and Depression Scale.
  • RESULTS: A total of 148 patients with end-stage renal disease (HD 100, PD 48) completed the study.
  • Among HD patients and their outpatient controls, the differences appeared to be unrelated to anxiety or depression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anxiety / complications. Depression / complications. Female. Humans. Male. Middle Aged. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2008 May;103(5):1317-8 [18477364.001]
  • (PMID = 17511755.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Leung AM, Vu HN, Nguyen KA, Thacker LR, Bear HD: Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res; 2010 Jun 1;161(1):83-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of surgical excision on survival of patients with stage IV breast cancer.
  • BACKGROUND: Non-palliative resection of the primary tumor in stage IV breast cancer is controversial.
  • Our aim was to determine whether surgery improves survival in stage IV patients.
  • METHODS: We reviewed records of all stage IV breast cancer patients (1990-2000) at our institution.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Bone Neoplasms / mortality. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Female. Humans. Kaplan-Meier Estimate. Linear Models. Middle Aged. Neoplasm Metastasis. Radiotherapy, Adjuvant. Retrospective Studies. Virginia / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19375721.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


73. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, Nalugoda F, Wabwire-Mangen F, Meehan MP, Quinn TC: Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis; 2005 May 1;191(9):1403-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.
  • BACKGROUND: We estimated rates of human immunodeficiency virus (HIV)-1 transmission per coital act in HIV-discordant couples by stage of infection in the index partner.
  • Rates of transmission per coital act were estimated by the index partner's stage of infection (recent seroconversion or prevalent or late-stage infection).
  • In adjusted models, early- and late-stage infection, higher HIV load, genital ulcer disease, and younger age of the index partner were significantly associated with higher rates of transmission.
  • CONCLUSIONS: The rate of HIV transmission per coital act was highest during early-stage infection.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Incidence. Male. Poisson Distribution. Time Factors. Uganda / epidemiology. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Sexually Transmitted Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Infect Dis. 2005 Oct 15;192(8):1497-9; author reply 1499-1500 [16170773.001]
  • [CommentIn] J Infect Dis. 2012 Feb 1;205(3):351-2 [22241799.001]
  • [CommentIn] J Infect Dis. 2005 May 1;191(9):1391-3 [15809893.001]
  • [CommentIn] J Infect Dis. 2006 Feb 15;193(4):604-5; author reply 605-6 [16425144.001]
  • (PMID = 15809897.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / 5P30HDS06826; United States / NIAID NIH HHS / AI / R01 AI34826
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


74. Zagrodzki P, Bartoń H, Walas S, Fołta M, Stompór T, Janusz-Grzybowska E, Drozdz M, Sułowicz W: Selenium status indices, laboratory data, and selected biochemical parameters in end-stage renal disease patients. Biol Trace Elem Res; 2007 Apr;116(1):29-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selenium status indices, laboratory data, and selected biochemical parameters in end-stage renal disease patients.
  • We investigated the relations between selenium status (SeS) parameters, indexes of nutrition, erythropoiesis, and uremic toxemia, serum electrolytes, and other biochemical markers in end-stage renal disease (ESRD) patients, as no multivariate statistical analysis concerning all of these parameters was performed so far.
  • SeS was evaluated by plasma Se concentration (plSe) and glutathione peroxidase (plGSHPx) activity in 69 uremic patients treated with hemodialysis (HD) and 40 healthy controls.
  • [MeSH-minor] Adult. Aluminum / blood. Biochemistry / methods. Female. Glutathione Peroxidase / metabolism. Humans. Male. Middle Aged. Multivariate Analysis. Parathyroid Hormone / blood

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634625.001).
  • [ISSN] 0163-4984
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone; CPD4NFA903 / Aluminum; EC 1.11.1.9 / Glutathione Peroxidase; H6241UJ22B / Selenium
  •  go-up   go-down


75. Abbas Tavallaii S, Ebrahimnia M, Shamspour N, Assari S: Effect of depression on health care utilization in patients with end-stage renal disease treated with hemodialysis. Eur J Intern Med; 2009 Jul;20(4):411-4
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of depression on health care utilization in patients with end-stage renal disease treated with hemodialysis.
  • BACKGROUND AND OBJECTIVES: Depression is regarded as the most common psychiatric abnormality in patients on hemodialysis (HD) for end-stage renal disease (ESRD).
  • [MeSH-minor] Adult. Aged. Ambulatory Care / utilization. Anxiety / epidemiology. Comorbidity. Emergency Service, Hospital / utilization. Female. Health Care Costs. Hospitals / utilization. Humans. Iran / epidemiology. Male. Middle Aged. Multivariate Analysis. Prospective Studies. Risk Factors. Socioeconomic Factors


76. Wang WH, Li YX, Song YW, Jin J, Liu YP, Wang SL, Zhou LQ, Liu XF, Yu ZH, Han JZ: [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease]. Zhonghua Zhong Liu Za Zhi; 2006 Mar;28(3):218-21
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease].
  • OBJECTIVE: To evaluate whether involved-field (IF) radiotherapy is equally effective and less toxic in comparison with extended-field (EF) radiotherapy for patients with early-stage Hodgkin's disease (HD) who received combined modality therapy.
  • METHODS: The data of 88 early-stage HD patients treated with combined modality therapy were retrospectively reviewed.
  • According to Ann Arbor classification, 12 patients (13.7%) had stage IA disease, 56 stage IIA (63.6%), and 20 IIB (22.7%).
  • CONCLUSION: Compared with extended-field radiotherapy, involved-field radiotherapy is equally effective and less toxic for patient with early-stage Hodgkin's disease treated with combined modality therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymphatic Irradiation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Leukopenia / etiology. Lymphatic Metastasis. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Retrospective Studies. Survival Rate. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875611.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


77. Vaccaro F, Mulè G, Cottone S, Soresi M, Giannitrapani L, Vadalà A, Sparacino V, Calabrese S, Picone FP, Montalto G, Cerasola G: Circulating levels of adhesion molecules in chronic kidney disease correlate with the stage of renal disease and with C-reactive protein. Arch Med Res; 2007 Jul;38(5):534-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating levels of adhesion molecules in chronic kidney disease correlate with the stage of renal disease and with C-reactive protein.
  • This study aims to evaluate circulating levels of intercellular adhesion molecules-1 (ICAM-1) and vascular cell adhesion molecules-1 (VCAM-1) in patients with predialysis CRF, on maintenance hemodialysis (HD) and after kidney transplantation (KTx) and to correlate them with some inflammation and nutritional indexes.
  • METHODS: Thirty two patients with predialysis CRF, 30 on maintenance HD, 36 after KTx and 28 subjects as a control group (C) were included in this study.
  • RESULTS: Serum levels of ICAM-1 and VCAM-1 were progressively higher from C to KTx patients, to those with CRF and those on HD (ANOVA for both; p <0.001).
  • TNFalpha values were lower in HD subjects than in CRF patients, even if in both groups TNFalpha levels were greater than in Tx and control subjects.
  • F and CRP were higher in CRF and HD vs. Tx and control subjects (ANOVA for both p <0.001).
  • CONCLUSIONS: Circulating levels of adhesion molecules in our study correlated positively with the stage of disease and with one of the inflammatory indexes (CRP), but not with nutritional indexes such as BMI, cholesterol and albumin.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. C-Reactive Protein / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Humans. Kidney Transplantation. Male. Middle Aged. Renal Dialysis. Tumor Necrosis Factor-alpha / blood

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560459.001).
  • [ISSN] 0188-4409
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Cell Adhesion Molecule-1; 126547-89-5 / Intercellular Adhesion Molecule-1; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


78. Koontz BF, Kirkpatrick JP, Clough RW, Prosnitz RG, Gockerman JP, Moore JO, Prosnitz LR: Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J Clin Oncol; 2006 Feb 1;24(4):605-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.
  • PURPOSE: The treatment of early-stage Hodgkin's disease (HD) has evolved from radiotherapy alone (RT) to combined-modality therapy (CMT) because of concerns about late adverse effects from high-dose subtotal nodal irradiation (STNI).
  • This retrospective study compares the long-term results of STNI with CMT using modestly reduced RT dose in the treatment of early-stage HD.
  • PATIENTS AND METHODS: Between 1982 and 2002, 111 patients with stage IA and IIA HD were treated definitively with RT (mean dose, 37.9 Gy); 70 patients were treated with CMT with low-dose involved-field radiotherapy (LDIFRT; mean dose, 25.5 Gy).
  • CONCLUSION: In this retrospective review, CMT with LDIFRT was effective in curing early-stage HD and was not associated with an increase in second malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Coronary Disease / prevention & control. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Cause of Death. Chemotherapy, Adjuvant / adverse effects. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Incidence. Lymph Nodes / radiation effects. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Retrospective Studies. Risk Assessment. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Feb 1;24(4):544-8 [16446326.001]
  • (PMID = 16446333.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Davidson MM, Nesti C, Palenzuela L, Walker WF, Hernandez E, Protas L, Hirano M, Isaac ND: Novel cell lines derived from adult human ventricular cardiomyocytes. J Mol Cell Cardiol; 2005 Jul;39(1):133-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel cell lines derived from adult human ventricular cardiomyocytes.
  • Background. - We have established proliferating human cardiomyocyte cell lines derived from non-proliferating primary cultures of adult ventricular heart tissue, using a novel method that may be applicable to many post-mitotic primary cultures.
  • EM ultra structural analysis revealed the presence of myofibrils in the subsarcolemmal region, indicating a precontractile developmental stage.

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913645.001).
  • [ISSN] 0022-2828
  • [Journal-full-title] Journal of molecular and cellular cardiology
  • [ISO-abbreviation] J. Mol. Cell. Cardiol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 9951061T; United States / NICHD NIH HHS / HD / HD32062
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Biomarkers
  •  go-up   go-down


80. Dong L, Jelinsky SA, Finger JN, Johnston DS, Kopf GS, Sottas CM, Hardy MP, Ge RS: Gene expression during development of fetal and adult Leydig cells. Ann N Y Acad Sci; 2007 Dec;1120:16-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression during development of fetal and adult Leydig cells.
  • After birth, SLCs that may differ from the fetal SLCs undergo lineage-specific commitment and give rise to adult Leydig cells (ALCs).
  • ALCs mark the point of maximum differentiation, and at this stage, the Leydig cell secretes testosterone at the highest rate.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184909.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD050570; United States / NIA NIH HHS / AG / R01 AG030598; United States / NICHD NIH HHS / HD / HD050570-01A2; United States / NIA NIH HHS / AG / R01 AG030598-01; United States / NICHD NIH HHS / HD / R01 HD050570-01A2; United States / NIA NIH HHS / AG / AG030598-01
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. McCurley AT, Callard GV: Characterization of housekeeping genes in zebrafish: male-female differences and effects of tissue type, developmental stage and chemical treatment. BMC Mol Biol; 2008 Nov 12;9:102
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of housekeeping genes in zebrafish: male-female differences and effects of tissue type, developmental stage and chemical treatment.
  • To identify housekeeping genes that are stably expressed under different experimental conditions, and thus suitable as normalizers for QPCR in zebrafish, the present study evaluated the expression of eight commonly used housekeeping genes as a function of stage and hormone/toxicant exposure during development, and by tissue type and sex in adult fish.
  • RESULTS: QPCR analysis was used to quantify mRNA levels of bactin1, tubulin alpha 1(tuba1), glyceraldehyde-3-phosphate dehydrogenase (gapdh), glucose-6-phosphate dehydrogenase (g6pd), TATA-box binding protein (tbp), beta-2-microglobulin (b2m), elongation factor 1 alpha (elfa), and 18s ribosomal RNA (18s) during development (2 - 120 hr postfertilization, hpf); in different tissue types (brain, eye, liver, heart, muscle, gonads) of adult males and females; and after treatment of embryos/larvae (24 - 96 hpf) with commonly used vehicles for administration and agents that represent known environmental endocrine disruptors.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2005 Sep 1;344(1):141-3 [16054107.001]
  • [Cites] Environ Toxicol. 2008 Feb;23(1):15-24 [18214933.001]
  • [Cites] Arch Biochem Biophys. 2005 Sep 15;441(2):151-67 [16122694.001]
  • [Cites] Genes Dev. 2005 Dec 1;19(23):2900-11 [16322560.001]
  • [Cites] Biotechniques. 2006 Feb;40(2):173-7 [16526406.001]
  • [Cites] Gen Comp Endocrinol. 2006 Jun;147(2):108-17 [16458310.001]
  • [Cites] Aquat Toxicol. 2006 Aug 23;79(2):167-75 [16844240.001]
  • [Cites] Toxicol Sci. 2007 Feb;95(2):356-68 [17093204.001]
  • [Cites] BMC Mol Biol. 2007;8:10 [17288598.001]
  • [Cites] Basic Res Cardiol. 2007 May;102(3):195-7 [17370033.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2007 May;39(5):384-90 [17492136.001]
  • [Cites] Aquat Toxicol. 2007 Aug 15;84(1):38-49 [17606305.001]
  • [Cites] BMC Mol Biol. 2007;8:67 [17697375.001]
  • [Cites] J Biotechnol. 1999 Oct 8;75(2-3):291-5 [10617337.001]
  • [Cites] Arch Dermatol Res. 1999 Dec;291(12):659-61 [10651167.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] J Biochem Biophys Methods. 2000 Nov 20;46(1-2):69-81 [11086195.001]
  • [Cites] Anal Biochem. 2001 Jan 1;288(1):99-102 [11141312.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):740-50 [11159846.001]
  • [Cites] J Bacteriol. 2001 Aug;183(16):4747-51 [11466277.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Nov;78(5):427-39 [11738553.001]
  • [Cites] Mol Cell Probes. 2001 Oct;15(5):307-11 [11735303.001]
  • [Cites] Development. 2002 Apr;129(7):1623-32 [11923199.001]
  • [Cites] Science. 2002 Apr 19;296(5567):557-9 [11964485.001]
  • [Cites] Biotechniques. 2002 Jun;32(6):1372-4, 1376, 1378-9 [12074169.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Mol Endocrinol. 2002 Aug;29(1):23-39 [12200227.001]
  • [Cites] Thorax. 2002 Sep;57(9):765-70 [12200519.001]
  • [Cites] Tissue Eng. 2002 Aug;8(4):551-9 [12201995.001]
  • [Cites] Anal Biochem. 2002 Oct 15;309(2):293-300 [12413463.001]
  • [Cites] Biotechnol Lett. 2004 Mar;26(6):509-15 [15127793.001]
  • [Cites] Biotechniques. 2004 Jul;37(1):112-4, 116, 118-9 [15283208.001]
  • [Cites] Nucleic Acids Res. 1993 Aug 11;21(16):3809-19 [8367299.001]
  • [Cites] Cell. 1996 Dec 13;87(6):969-77 [8978602.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jun 16;259(3):523-6 [10364451.001]
  • [Cites] Genes Immun. 2005 Jun;6(4):279-84 [15815687.001]
  • [Cites] Gen Comp Endocrinol. 2005 Sep 15;143(3):287-99 [15925369.001]
  • (PMID = 19014500.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / L30 HD073897; United States / NIEHS NIH HHS / ES / P42 ES007381; United States / NICHD NIH HHS / HD / 2T 32HD073897; United States / NIEHS NIH HHS / ES / P42ES07381
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Zebrafish Proteins
  • [Other-IDs] NLM/ PMC2588455
  •  go-up   go-down


82. Chang JW, Lee EK, Kim TH, Min WK, Chun S, Lee KU, Kim SB, Park JS: Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Am J Nephrol; 2007;27(1):70-4
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study.
  • Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, is not only a cause of endothelial dysfunction, but also a predictor of the cardiovascular outcome in end-stage renal disease (ESRD) patients on hemodialysis (HD).
  • We investigated whether ALA could decrease the plasma level of ADMA in diabetic ESRD patients on HD.
  • METHODS: Fifty patients undergoing HD three times per week were randomized to a treatment group receiving ALA 600 mg/day for 12 weeks or a control group.
  • [MeSH-minor] Adult. Biomarkers / blood. C-Reactive Protein / metabolism. Cholesterol / blood. Chromatography, High Pressure Liquid. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Hemoglobin A, Glycosylated / metabolism. Humans. Lipoproteins, LDL / blood. Male. Middle Aged. Nitric Oxide Synthase / antagonists & inhibitors. Oxidation-Reduction / drug effects. Pilot Projects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Diabetic Kidney Problems.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17259696.001).
  • [ISSN] 1421-9670
  • [Journal-full-title] American journal of nephrology
  • [ISO-abbreviation] Am. J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers; 0 / Hemoglobin A, Glycosylated; 0 / Lipoproteins, LDL; 0 / oxidized low density lipoprotein; 30315-93-6 / N,N-dimethylarginine; 73Y7P0K73Y / Thioctic Acid; 9007-41-4 / C-Reactive Protein; 94ZLA3W45F / Arginine; 97C5T2UQ7J / Cholesterol; EC 1.14.13.39 / Nitric Oxide Synthase
  •  go-up   go-down


83. Wilson EM, Green JR: Coordinative organization of lingual propulsion during the normal adult swallow. Dysphagia; 2006 Oct;21(4):226-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coordinative organization of lingual propulsion during the normal adult swallow.
  • The purpose of this investigation was to quantitatively describe the coordinative organization of lingual propulsion during the normal adult swallow.
  • Movement of four pellets placed on specific tongue regions were tracked in 36 healthy adult participants while they swallowed 10 cc of water across five discrete trials.
  • Future work is needed to determine if the absence of the observed coordinative organization of lingual propulsion is indicative of oral stage dysphagia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Speech Lang Hear Res. 2002 Aug;45(4):651-62 [12199396.001]
  • [Cites] J Acoust Soc Am. 2003 May;113(5):2820-33 [12765399.001]
  • [Cites] J Speech Lang Hear Res. 2004 Apr;47(2):342-52 [15157134.001]
  • [Cites] J Clin Ultrasound. 1983 Nov-Dec;11(9):485-90 [6417184.001]
  • [Cites] Invest Radiol. 1984 Mar-Apr;19(2):82-6 [6398320.001]
  • [Cites] Dysphagia. 1986;1(2):78-83 [3527582.001]
  • [Cites] Dysphagia. 1988;3(2):79-84 [3271656.001]
  • [Cites] Dev Med Child Neurol. 1990 Mar;32(3):223-9 [2311826.001]
  • [Cites] Dysphagia. 1989;4(2):90-4 [2640185.001]
  • [Cites] Dysphagia. 1996 Fall;11(4):239-47 [8870350.001]
  • [Cites] J Speech Lang Hear Res. 1998 Aug;41(4):771-85 [9712125.001]
  • [Cites] Dysphagia. 1999 Winter;14(1):31-42 [9828272.001]
  • [Cites] Dysphagia. 1999 Summer;14(3):131-8 [10341108.001]
  • [Cites] Dysphagia. 1999 Fall;14(4):228-32 [10467048.001]
  • [Cites] Am J Orthod. 1965 Aug;51:566-94 [14331958.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2003 Sep;112(9 Pt 1):768-76 [14535560.001]
  • [Cites] J Speech Lang Hear Res. 2000 Feb;43(1):239-55 [10668666.001]
  • [Cites] J Speech Lang Hear Res. 2001 Feb;44(1):95-107 [11218113.001]
  • (PMID = 17221289.001).
  • [ISSN] 0179-051X
  • [Journal-full-title] Dysphagia
  • [ISO-abbreviation] Dysphagia
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / F31 DC006337; United States / NIDCD NIH HHS / DC / R01 DC006463; United States / NIDCD NIH HHS / DC / R03 DC004643; United States / NICHD NIH HHS / HD / T32 HD007489; United States / NIDCD NIH HHS / DC / R01 DC006463-01A1; United States / NIDCD NIH HHS / DC / T32 DC005359; United States / NIDCD NIH HHS / DC / R01 DC009890; United States / NIDCD NIH HHS / DC / T32 DC05359; United States / NICHD NIH HHS / HD / T32 HD07489
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS195929; NLM/ PMC2866114
  •  go-up   go-down


84. Song YS, Jung H, Shim J, Oh C, Shin GT, Kim H: Survival analysis of Korean end-stage renal disease patients according to renal replacement therapy in a single center. J Korean Med Sci; 2007 Feb;22(1):81-8
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival analysis of Korean end-stage renal disease patients according to renal replacement therapy in a single center.
  • This study was to investigate clinical characteristics and any differential trends in survival among renal replacement therapy (hemodialysis [HD], peritoneal dialysis [PD], and kidney transplantation [KT]) in Korean end-stage renal disease (ESRD) population.
  • In adjusted Cox survival curves, the KT patients had the best survival rate, and the HD patients had better survival than PD patients.
  • 1) The risk of death for PD and HD was not proportional over time, 2) The relative risk of PD was similar or lower than that of HD for the first 12 months, but it became higher at later period.
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Kidney Transplantation. Male. Middle Aged. Morbidity. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int. 2003 Sep;64(3):1071-9 [12911559.001]
  • [Cites] Kidney Int Suppl. 1983 Dec;16:S199-203 [6429404.001]
  • [Cites] Arch Intern Med. 1986 Jun;146(6):1138-43 [3718101.001]
  • [Cites] Lancet. 1987 Nov 14;2(8568):1105-9 [2890018.001]
  • [Cites] Adv Perit Dial. 1990;6:181-5 [1982804.001]
  • [Cites] Perit Dial Int. 1991;11(2):118-27 [1854867.001]
  • [Cites] Nephrol Dial Transplant. 1991;6(6):444-51 [1876287.001]
  • [Cites] CMAJ. 1994 Apr 1;150(7):1067-71 [8137186.001]
  • [Cites] Kidney Int. 1994 Apr;45(4):1163-9 [8007587.001]
  • [Cites] Am J Kidney Dis. 1995 Jan;25(1):165-75 [7810521.001]
  • [Cites] Am J Kidney Dis. 1995 Jul;26(1):220-8 [7611256.001]
  • [Cites] J Am Soc Nephrol. 1995 Aug;6(2):177-83 [7579082.001]
  • [Cites] Perit Dial Int. 1996;16 Suppl 1:S393-7 [8728230.001]
  • [Cites] Perit Dial Int. 1996 May-Jun;16(3):276-87 [8761542.001]
  • [Cites] Adv Perit Dial. 1996;12:302-6 [8865924.001]
  • [Cites] Kidney Int. 1996 Sep;50(3):1013-8 [8872978.001]
  • [Cites] Perit Dial Int. 1996 Nov-Dec;16(6):628-33 [8981533.001]
  • [Cites] Nephrol Dial Transplant. 1997;12 Suppl 1:65-7 [9075232.001]
  • [Cites] Am J Kidney Dis. 1997 Sep;30(3):334-42 [9292560.001]
  • [Cites] Nephron. 1997;77(1):13-28 [9380234.001]
  • [Cites] J Am Soc Nephrol. 1998 Feb;9(2):267-76 [9527403.001]
  • [Cites] Nephrol Dial Transplant. 1998 Jul;13(7):1782-6 [9681728.001]
  • [Cites] Perit Dial Int. 1998 Sep-Oct;18(5):478-84 [9848625.001]
  • [Cites] J Am Soc Nephrol. 1999 Feb;10(2):354-65 [10215336.001]
  • [Cites] Kidney Int. 2004 Dec;66(6):2389-401 [15569331.001]
  • [Cites] Am J Kidney Dis. 1999 Dec;34(6):1065-74 [10585316.001]
  • [Cites] J Am Soc Nephrol. 2000 Jan;11(1):116-25 [10616847.001]
  • [Cites] J Am Soc Nephrol. 2000 Sep;11(9):1726-34 [10966498.001]
  • [Cites] J Am Soc Nephrol. 2002 May;13(5):1307-20 [11961019.001]
  • [Cites] J Am Soc Nephrol. 2003 Feb;14(2):415-24 [12538742.001]
  • (PMID = 17297256.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693574
  •  go-up   go-down


85. Naskalski JW, Kapusta M, Fedak D, Dumnicka P, Kuśnierz-Cabala B, Kuźniewski M, Sułowicz W: Effect of hemodialysis on acid leukocyte-type ribonuclease, alkaline ribonuclease and polymorphonuclear elastase serum levels in patients with end-stage renal disease. Nephron Clin Pract; 2009;112(4):c248-54
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of hemodialysis on acid leukocyte-type ribonuclease, alkaline ribonuclease and polymorphonuclear elastase serum levels in patients with end-stage renal disease.
  • BACKGROUND: Low-molecular-weight proteins (LMWPs) are substances of molecular weights 10-35 kDa, which accumulate in plasma of patients with end-stage renal disease (ESRD) due to the abolishment of plasma renal filtration.
  • AIM: The influence of hemodialysis (HD) on the release of some LMWPs from leukocytes was assessed by comparing levels of serum pancreatic-type alkaline RNase and leukocyte-type acid RNase as well as polymorphonuclear (PMN) elastase.
  • METHODS: The mentioned proteins were assayed in 58 ESRD patients on HD prior and after the dialysis session and compared with the results obtained from 36 healthy subjects.
  • The levels of elastase and acid and alkaline RNase were correlated with HD parameters, residual diuresis, predialysis concentrations of serum creatinine, urea and albumin as well as pre- and postdialysis granulocyte count.
  • There is a negative correlation between pre- and postdialysis differences in levels of acid and alkaline RNases (r = -0.3542; p = 0.008), indicating that HD induces liberation of a factor suppressing alkaline RNase.
  • [MeSH-minor] Adult. Female. Humans. Kidney / enzymology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19546584.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 3.1.- / Ribonucleases; EC 3.4.21.37 / Leukocyte Elastase
  •  go-up   go-down


86. Alexander JM, Leveno KJ, Rouse DJ, Landon MB, Gilbert S, Spong CY, Varner MW, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, O'Sullivan MJ, Sibai BM, Langer O, Gabbe SG, National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU): Comparison of maternal and infant outcomes from primary cesarean delivery during the second compared with first stage of labor. Obstet Gynecol; 2007 Apr;109(4):917-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of maternal and infant outcomes from primary cesarean delivery during the second compared with first stage of labor.
  • OBJECTIVE: To compare maternal and neonatal outcomes when primary cesarean delivery is performed in the second stage of labor compared with the first stage.
  • RESULTS: A total of 11,981 cesarean deliveries were available for analysis: 9,265 were performed in the first stage and 2,716 in the second stage.
  • Cesarean deliveries performed in the second stage were associated with longer operative times, epidural analgesia, chorioamnionitis, and higher birth weight (all P<.001).
  • The maternal composite index was slightly increased in women undergoing cesarean delivery in the second stage of labor, primarily due to uterine atony, uterine incision extension, and incidental cystotomy.
  • CONCLUSION: Cesarean delivery in the second stage of labor is associated with slightly increased maternal but not neonatal composite morbidity.
  • [MeSH-major] Apgar Score. Cesarean Section / adverse effects. Labor Stage, First. Labor Stage, Second. Obstetric Labor Complications / epidemiology. Pregnancy Outcome
  • [MeSH-minor] Adult. Birth Injuries / epidemiology. Female. Humans. Infant Mortality. Infant, Newborn. Intensive Care, Neonatal. Intraoperative Complications. Intubation. Morbidity. Pregnancy. Seizures / epidemiology

  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • MedlinePlus Health Information. consumer health - Childbirth Problems.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400854.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD21410; United States / NICHD NIH HHS / HD / HD21414; United States / NICHD NIH HHS / HD / HD27860; United States / NICHD NIH HHS / HD / HD27861; United States / NICHD NIH HHS / HD / HD27869; United States / NICHD NIH HHS / HD / HD27905; United States / NICHD NIH HHS / HD / HD27915; United States / NICHD NIH HHS / HD / HD27917; United States / NICHD NIH HHS / HD / HD34116; United States / NICHD NIH HHS / HD / HD34122; United States / NICHD NIH HHS / HD / HD34136; United States / NICHD NIH HHS / HD / HD34208; United States / NICHD NIH HHS / HD / HD34210; United States / NICHD NIH HHS / HD / HD36801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


87. Huang KC, Hsu SP, Yang CC, Ou-Yang P, Lee KT, Morisawa S, Otsubo K, Chien CT: Electrolysed-reduced water dialysate improves T-cell damage in end-stage renal disease patients with chronic haemodialysis. Nephrol Dial Transplant; 2010 Aug;25(8):2730-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrolysed-reduced water dialysate improves T-cell damage in end-stage renal disease patients with chronic haemodialysis.
  • BACKGROUND: T-cell damage by increased oxidative stress in end-stage renal disease (ESRD) patients undergoing chronic haemodialysis (HD) led to the increased T-cell apoptosis and the alteration of surface markers and Th1/Th2 ratio in CD4(+) T lymphocytes.
  • Antioxidant electrolysed-reduced water (ERW) was used as the dialysate in ESRD patients undergoing chronic HD to test for improved oxidative stress-related T-cell apoptosis, alterations of surface markers and intracellular cytokine profile.
  • CONCLUSION: One-year ERW treatment effectively ameliorated T-cell apoptosis, altered CD25-related surface markers and intracellular cytokine profile in the HD patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. C-Reactive Protein / metabolism. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / pathology. Case-Control Studies. Female. Humans. Interleukin-2 Receptor alpha Subunit / metabolism. Interleukin-6 / metabolism. Longitudinal Studies. Male. Middle Aged. Th1 Cells / pathology. Th2 Cells / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190245.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dialysis Solutions; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Interleukin-6; 0 / superoxidized water; 9007-41-4 / C-Reactive Protein; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


88. Huang HD, Lin FJ, Li XJ, Wang LR, Jiang GR: Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy. Chin Med J (Engl); 2010 Nov;123(22):3238-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy.
  • BACKGROUND: Genetic variability in the renin-angiotensin-aldosterone system may modify renal responses to injury and disease progression.
  • We determined the presence of these polymorphisms in 130 Chinese patients with IgAN, including 47 patients with end-stage renal disease (ESRD) and 120 healthy Chinese subjects, to assess their impact on the susceptibility to disease and the liability of progression to ESRD.
  • [MeSH-minor] Adult. Angiotensinogen / genetics. Asian Continental Ancestry Group / genetics. Cytochrome P-450 CYP11B2 / genetics. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Peptidyl-Dipeptidase A / genetics. Polymorphism, Genetic / genetics. Receptor, Angiotensin, Type 1 / genetics

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21163122.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptor, Angiotensin, Type 1; 11002-13-4 / Angiotensinogen; EC 1.14.15.4 / Cytochrome P-450 CYP11B2; EC 3.4.15.1 / Peptidyl-Dipeptidase A
  •  go-up   go-down


89. Cornelis T, Rioux JP, Bargman JM, Chan CT: Home dialysis is a successful strategy in nonrenal solid organ transplant recipients with end-stage renal disease. Nephrol Dial Transplant; 2010 Oct;25(10):3425-9
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Home dialysis is a successful strategy in nonrenal solid organ transplant recipients with end-stage renal disease.
  • BACKGROUND: Chronic kidney disease (CKD) is a common complication of solid organ transplantation with a substantial risk of progression to end-stage renal disease (ESRD).
  • Three patients switched to in-centre conventional HD during follow-up and eight patients died.
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Hospitalization / statistics & numerical data. Humans. Male. Middle Aged. Peritonitis / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576722.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


90. Bessler JB, Andersen EC, Villeneuve AM: Differential localization and independent acquisition of the H3K9me2 and H3K9me3 chromatin modifications in the Caenorhabditis elegans adult germ line. PLoS Genet; 2010 Jan 22;6(1):e1000830
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential localization and independent acquisition of the H3K9me2 and H3K9me3 chromatin modifications in the Caenorhabditis elegans adult germ line.
  • Here we investigate the relationships between dimethyl and trimethyl modifications on lysine 9 of histone H3 (H3K9me2 and H3K9me3) in the adult Caenorhabditis elegans germ line.
  • While H3K9me2 is enriched on unpaired sex chromosomes and undergoes dynamic changes as germ cells progress through meiotic prophase, we demonstrate here that H3K9me3 is not enriched on unpaired sex chromosomes and localizes to all chromosomes in all germ cells in adult hermaphrodites and until the primary spermatocyte stage in males.
  • MET-2, a member of the SETDB histone methyltransferase (HMTase) family, is required for all detectable germline H3K9me2 but is dispensable for H3K9me3 in adult germ cells.
  • Conversely, we show that the HMTase MES-2, an E(z) homolog responsible for H3K27 methylation in adult germ cells, is required for much of the germline H3K9me3 but is dispensable for H3K9me2.
  • Further, these and other data support a model in which these two modifications function independently in adult C. elegans germ cells.

  • COS Scholar Universe. author profiles.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12691-6 [17652514.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):6857-68 [16055700.001]
  • [Cites] Mol Cell. 2003 Dec;12(6):1577-89 [14690609.001]
  • [Cites] Dev Biol. 2007 Jun 1;306(1):1-9 [17434473.001]
  • [Cites] Mol Cell Biol. 2007 Feb;27(4):1271-9 [17158930.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1051-63 [16360035.001]
  • [Cites] BMC Dev Biol. 2007;7:38 [17466069.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Curr Opin Cell Biol. 2001 Jun;13(3):263-73 [11343896.001]
  • [Cites] Cell. 2006 May 5;125(3):467-81 [16603238.001]
  • [Cites] Dev Cell. 2006 Dec;11(6):817-29 [17141157.001]
  • [Cites] Curr Biol. 2005 Nov 8;15(21):1972-8 [16271877.001]
  • [Cites] PLoS One. 2008;3(5):e2234 [18493619.001]
  • [Cites] PLoS Genet. 2007 May 11;3(5):e76 [17500594.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15502-7 [9860998.001]
  • [Cites] Development. 2007 Aug;134(16):2991-9 [17634190.001]
  • [Cites] Genes Dev. 2002 Sep 15;16(18):2428-42 [12231631.001]
  • [Cites] Genetics. 1994 Jan;136(1):119-27 [8138150.001]
  • [Cites] Mol Cell. 2003 Aug;12(2):475-87 [14536086.001]
  • [Cites] Cell. 2002 Oct 18;111(2):185-96 [12408863.001]
  • [Cites] Dev Cell. 2009 May;16(5):699-710 [19460346.001]
  • [Cites] Biotechniques. 2004 May;36(5):778-80, 782 [15152596.001]
  • [Cites] Development. 2006 Oct;133(19):3907-17 [16968818.001]
  • [Cites] Science. 2005 Dec 9;310(5754):1683-6 [16339446.001]
  • [Cites] Cell. 2004 Aug 20;118(4):439-52 [15315757.001]
  • [Cites] PLoS Genet. 2009 Aug;5(8):e1000611 [19696886.001]
  • [Cites] Mol Cell. 2007 Oct 12;28(1):1-13 [17936700.001]
  • [Cites] Development. 2002 Jan;129(2):479-92 [11807039.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16583-7 [15536132.001]
  • [Cites] Cell. 2007 Feb 23;128(4):693-705 [17320507.001]
  • [Cites] Genetics. 1991 Dec;129(4):1061-72 [1783292.001]
  • [Cites] Mol Cell Biol. 1985 Dec;5(12):3484-96 [3837845.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1578-83 [10887151.001]
  • [Cites] Genetics. 2006 Jul;173(3):1571-83 [16624902.001]
  • [Cites] Cell. 2002 Oct 18;111(2):197-208 [12408864.001]
  • [Cites] Genetics. 1997 May;146(1):227-38 [9136012.001]
  • [Cites] Mol Cell. 2003 Dec;12(6):1591-8 [14690610.001]
  • [Cites] Nat Genet. 2004 Jan;36(1):100-5 [14702046.001]
  • [Cites] Nat Rev Genet. 2007 Jan;8(1):35-46 [17173056.001]
  • [Cites] Mol Cell. 2000 Sep;6(3):605-16 [11030340.001]
  • [Cites] PLoS Genet. 2008 Jan;4(1):e16 [18208336.001]
  • [Cites] EMBO J. 2005 Jul 20;24(14):2613-23 [15990876.001]
  • [Cites] Oncogene. 2002 Jan 3;21(1):148-52 [11791185.001]
  • [Cites] Genetics. 1979 Jan;91(1):67-94 [17248881.001]
  • [Cites] Genome Dyn. 2009;5:43-55 [18948706.001]
  • [Cites] Curr Biol. 2004 Sep 21;14(18):1639-43 [15380065.001]
  • [Cites] Genes Dev. 2002 Apr 15;16(8):919-32 [11959841.001]
  • [Cites] EMBO Rep. 2002 Mar;3(3):235-41 [11850401.001]
  • [Cites] Genetics. 1994 Mar;136(3):887-902 [8005443.001]
  • [Cites] Dev Biol. 1979 Dec;73(2):304-21 [499670.001]
  • [Cites] Genetics. 2007 Apr;175(4):2029-37 [17237503.001]
  • [Cites] Curr Top Dev Biol. 2006;76:185-215 [17118267.001]
  • [Cites] Mol Cell. 2000 Mar;5(3):435-43 [10882129.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1037-50 [16360034.001]
  • [Cites] Nat Genet. 2009 Mar;41(3):376-81 [19182803.001]
  • [Cites] Mol Cell. 2005 Aug 5;19(3):381-91 [16061184.001]
  • [Cites] Development. 1999 Jun;126(11):2483-94 [10226007.001]
  • (PMID = 20107519.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K99 HD059068; United States / NIGMS NIH HHS / GM / R01 GM067268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins; 0 / Chromatin; 0 / Histones; 0 / Mucoproteins; 0 / lysin, gastropoda; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / Met-2 protein, C elegans
  • [Other-IDs] NLM/ PMC2809760
  •  go-up   go-down


91. Estes CS, Beauchamp CP, Clarke HD, Spangehl MJ: A two-stage retention débridement protocol for acute periprosthetic joint infections. Clin Orthop Relat Res; 2010 Aug;468(8):2029-38
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-stage retention débridement protocol for acute periprosthetic joint infections.
  • QUESTIONS/PURPOSES: We determined the ability of this two-stage débridement to control infection.
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Arthroplasty, Replacement, Hip. Arthroplasty, Replacement, Knee. Bone Cements. Combined Modality Therapy. Drug Delivery Systems. Female. Hip Prosthesis / adverse effects. Hip Prosthesis / microbiology. Humans. Knee Prosthesis / adverse effects. Knee Prosthesis / microbiology. Male. Middle Aged. Reoperation. Retrospective Studies. Treatment Failure

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1999 Oct;81(10):1434-45 [10535593.001]
  • [Cites] Clin Orthop Relat Res. 2008 Nov;466(11):2628-33 [18781372.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):23-8 [12360003.001]
  • [Cites] Clin Orthop Relat Res. 2002 Nov;(404):125-31 [12439250.001]
  • [Cites] Clin Infect Dis. 2003 Apr 1;36(7):845-9 [12652384.001]
  • [Cites] J Arthroplasty. 2003 Oct;18(7 Suppl 1):22-6 [14560406.001]
  • [Cites] J Bone Joint Surg Am. 1974 Mar;56(2):273-84 [4452686.001]
  • [Cites] Clin Orthop Relat Res. 1976 Jun;(117):221-40 [776484.001]
  • [Cites] J Arthroplasty. 1990 Mar;5(1):35-9 [2319246.001]
  • [Cites] J Bone Joint Surg Am. 1990 Oct;72(9):1383-90 [2229118.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):105-12 [1959256.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):113-8 [1959257.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):98-104 [1959294.001]
  • [Cites] Clin Orthop Relat Res. 1992 May;(278):244-52 [1563160.001]
  • [Cites] J Bone Joint Surg Am. 1996 Apr;78(4):512-23 [8609130.001]
  • [Cites] Clin Orthop Relat Res. 1996 Oct;(331):146-50 [8895631.001]
  • [Cites] J Arthroplasty. 1996 Dec;11(8):931-8 [8986571.001]
  • [Cites] J Arthroplasty. 1997 Jun;12(4):426-33 [9195319.001]
  • [Cites] JAMA. 1998 May 20;279(19):1537-41 [9605897.001]
  • [Cites] J Bone Joint Surg Am. 1998 Sep;80(9):1306-13 [9759815.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1999 Mar;28(3):161-5 [10195839.001]
  • [Cites] J Bone Joint Surg Am. 1999 May;81(5):672-83 [10360695.001]
  • [Cites] Arthroscopy. 2005 Mar;21(3):303-6 [15756183.001]
  • [Cites] J Bone Joint Surg Am. 2005 Jul;87(7):1415-22 [15995106.001]
  • [Cites] Clin Microbiol Infect. 2006 May;12(5):433-9 [16643519.001]
  • [Cites] Clin Orthop Relat Res. 2007 Aug;461:130-5 [17438469.001]
  • [Cites] J Bone Joint Surg Am. 2008 Aug;90(8):1637-43 [18676892.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):8-15 [12360001.001]
  • (PMID = 20224958.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bone Cements
  • [Other-IDs] NLM/ PMC2895840
  •  go-up   go-down


92. Squitieri F, Cannella M, Simonelli M, Sassone J, Martino T, Venditti E, Ciammola A, Colonnese C, Frati L, Ciarmiello A: Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neurosci Ther; 2009;15(1):1-11
MedlinePlus Health Information. consumer health - Huntington's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease.
  • Searching brain and peripheral biomarkers is a requisite to cure Huntington's disease (HD).
  • To search for markers indicating the rate of brain neurodegenerative changes in the various disease stages, we quantified changes in brain atrophy in subjects with HD.
  • We analyzed the cross-sectional and longitudinal rate of brain atrophy, quantitatively measured by fully-automated multiparametric magnetic resonance imaging, as fractional gray matter (GM, determining brain cortex volume), white matter (WM, measuring the volume of axonal fibers), and corresponding cerebral spinal fluid (CSF, a measure of global brain atrophy), in 94 gene-positive subjects with presymptomatic to advanced HD, and age-matched healthy controls.
  • Each of the three brain compartments we studied (WM, GM, and CSF) had a diverse role and their time courses differed in the development of HD.
  • Its decrease was associated with decreased serum brain-derived-neurotrophic-factor and started even many years before onset symptoms, then decreased slowly in a nonlinear manner during the various symptomatic HD stages.
  • WM volume loss also began in the presymptomatic stage of HD a few years before manifest symptoms appear, rapidly decreasing near to the zone-of-onset.
  • The progressive CSF increase depended on CAG mutation size and continued linearly until the last stages of HD, perhaps representing the best marker of progression rate and severity in HD (R(2)= 0.25, P < 0.0001).
  • [MeSH-major] Brain / pathology. Huntington Disease / pathology. Mutation
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Aged. Atrophy. Disease Progression. Female. Humans. Male. Middle Aged. Trinucleotide Repeats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19228174.001).
  • [ISSN] 1755-5949
  • [Journal-full-title] CNS neuroscience & therapeutics
  • [ISO-abbreviation] CNS Neurosci Ther
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP06181
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Bradran A, Nasri H: Association between white blood cell count and levels of serum homocysteine in end-stage renal failure patients treating with hemodialysis. J Ayub Med Coll Abbottabad; 2006 Jan-Mar;18(1):22-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between white blood cell count and levels of serum homocysteine in end-stage renal failure patients treating with hemodialysis.
  • BACKGROUND: In hemodialysis patients, plasma levels of total homocysteine are influenced by nutritional status in patients with chronic kidney disease.
  • To investigate the association between serum homocysteine (Hcy) level as a marker of nutritional status and WBC counts as a marker of inflammation, a cross-sectional study was conducted on patients with end-stage renal disease (ESRD), who were undergoing maintenance hemodialysis treatment.
  • RESULTS: Total patients were 36 (f=15 m=21), consisting of 25 non-diabetic HD patients and 11 diabetic HD patients.
  • [MeSH-minor] Adult. Aged. Cross-Sectional Studies. Female. Humans. Inflammation / blood. Male. Middle Aged. Nutritional Status

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773964.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0LVT1QZ0BA / Homocysteine
  •  go-up   go-down


94. Huang KC, Yang CC, Hsu SP, Lee KT, Liu HW, Morisawa S, Otsubo K, Chien CT: Electrolyzed-reduced water reduced hemodialysis-induced erythrocyte impairment in end-stage renal disease patients. Kidney Int; 2006 Jul;70(2):391-8
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrolyzed-reduced water reduced hemodialysis-induced erythrocyte impairment in end-stage renal disease patients.
  • Chronic hemodialysis (HD) patients increase erythrocyte susceptibility to hemolysis and impair cell survival.
  • We explored whether electrolyte-reduced water (ERW) could palliate HD-evoked erythrocyte impairment and anemia.
  • Forty-three patients undergoing chronic HD were enrolled and received ERW administration for 6 month.
  • We evaluated oxidative stress in blood and plasma, erythrocyte methemoglobin (metHb)/ferricyanide reductase activity, plasma metHb, and proinflammatory cytokines in the chronic HD patients without treatment (n=15) or with vitamin C (VC)- (n=15), vitamin E (VE)-coated dialyzer (n=15), or ERW treatment (n=15) during an HD course.
  • The patients showed marked increases (15-fold) in blood reactive oxygen species, mostly H(2)O(2), after HD without any treatment.
  • HD resulted in decreased plasma VC, total antioxidant status, and erythrocyte metHb/ferricyanide reductase activity and increased erythrocyte levels of phosphatidylcholine hydroperoxide (PCOOH) and plasma metHb.
  • Antioxidants treatment significantly palliated single HD course-induced oxidative stress, plasma and RBC PCOOH, and plasma metHb levels, and preserved erythrocyte metHb /ferricyanide reductase activity in an order VC>ERW>VE-coated dialyzer.
  • Six-month ERW treatment increased hematocrit and attenuated proinflammatory cytokines profile in the HD patients.
  • In conclusion, ERW treatment administration is effective in palliating HD-evoked oxidative stress, as indicated by lipid peroxidation, hemolysis, and overexpression of proinflammatory cytokines in HD patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antioxidants / administration & dosage. Ascorbic Acid / administration & dosage. Biomarkers. Cell Survival. Electrolysis. Female. Hematocrit. Humans. Male. Membranes, Artificial. Methemoglobin / metabolism. Middle Aged. Oxidative Stress / drug effects. Reactive Oxygen Species / metabolism. Vitamin E / administration & dosage. Water / chemistry

  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760903.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers; 0 / Hemodialysis Solutions; 0 / Membranes, Artificial; 0 / Reactive Oxygen Species; 059QF0KO0R / Water; 1406-18-4 / Vitamin E; 9008-37-1 / Methemoglobin; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


95. Liakopoulos V, Eleftheriadis T, Kyropoulos T, Voliotis G, Potamianos S, Zengos N, Stefanidis I, Heintz B: Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease. Ren Fail; 2005;27(3):315-21
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.
  • Atherosclerosis is by far the leading cause of mortality and morbidity in patients with end stage renal disease undergoing chronic hemodialysis (HD).
  • The aim of this study was to clarify the influence of the HD procedure on the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.
  • We evaluated 35 clinically stable patients (18 males, 17 females, mean age 61 +/- 12) on chronic HD treatment.
  • Blood was drawn before, every hour during, and after a single HD session in each patient.
  • At 30 min into the HD session (n=31, 20 low-flux HD, 11 high-flux HD) blood was drawn simultaneously from the entrance and the exit line of the dialyzer.
  • Plasma levels of sVCAM-1 were elevated in patients with end stage renal disease before the beginning of the dialysis session when compared to healthy controls (1449 +/- 497 ng/mL vs. 691 +/- 118 ng/mL).
  • Our study confirms that in chronic HD patients serum levels for sVCAM-1 are elevated.
  • The levels of adhesion molecules are not affected by the HD procedure.
  • The functional role of sVCAM-1 and sICAM-1, the exact renal contribution to their metabolism, and their role as markers of atherosclerosis in chronic renal disease need further evaluation.
  • [MeSH-minor] Adult. Arteriosclerosis / blood. Arteriosclerosis / etiology. Biomarkers / blood. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Humans. Male. Middle Aged. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957549.001).
  • [ISSN] 0886-022X
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vascular Cell Adhesion Molecule-1; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


96. Thorman R, Neovius M, Hylander B: Prevalence and early detection of oral fungal infection: a cross-sectional controlled study in a group of Swedish end-stage renal disease patients. Scand J Urol Nephrol; 2009;43(4):325-30
MedlinePlus Health Information. consumer health - Mouth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and early detection of oral fungal infection: a cross-sectional controlled study in a group of Swedish end-stage renal disease patients.
  • Generalized fungal infection increases both morbidity and mortality in end-stage renal disease (ESRD) patients.
  • In total, 34 patients were treated with peritoneal dialysis (PD) and 59 with haemodialysis (HD).
  • An extensive OFI, defined as frequent fungal hyphae formations in oral mucosal smear layers, was found in 3% of the PD and 17% of the HD patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antifungal Agents / therapeutic use. Case-Control Studies. Cross-Sectional Studies. Dental Plaque / etiology. Female. Humans. Male. Middle Aged. Peritoneal Dialysis. Prevalence. Renal Dialysis. Risk Factors. Sweden / epidemiology. Xerostomia / etiology

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19363743.001).
  • [ISSN] 1651-2065
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


97. Chang JH, Yoon SJ, Han SH, Shin SK, Jeon DW, Yang JY, Kang EW: The impact of dialysis modality on arterial stiffness in patients with end-stage renal disease. Ren Fail; 2010;32(8):947-53
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of dialysis modality on arterial stiffness in patients with end-stage renal disease.
  • BACKGROUND: Arterial stiffness determined by brachial-ankle pulse wave velocity (baPWV) has been established as a powerful predictor of cardiovascular mortality in hemodialysis (HD) patients.
  • Therefore, we conducted a cross-sectional study to compare arterial wall properties and cardiac function between patients treated with continuous ambulatory peritoneal dialysis (CAPD) and those with HD who were matched for age, dialysis duration, and blood pressure.
  • METHODS: baPWV and transthoracic echocardiography (TTE) were performed in HD patients (n = 23) after 1 h of midweek dialysis session and CAPD patients (n = 26) with empty abdomen after drainage of dialysate.
  • RESULTS: baPWV was significantly higher in HD patients than in CAPD patients (18.1 +/- 2.8 vs. 16.1 +/- 2.7 m/s, p = 0.015).
  • TTE revealed significantly increased E/E', left atrial volume index (LAVI), and inferior vena cava (IVC) diameter index in HD patients compared with CAPD patients (p < 0.05).
  • In a multivariate regression analysis adjusted for dialysis modality, age, systolic BP, residual glomerular filtration rate, diabetes, and echocardiographic parameters, HD was independently associated with increased baPWV.
  • CONCLUSION: This study showed that HD patients had significantly increased arterial stiffness and severe diastolic dysfunction compared with CAPD patients.
  • [MeSH-minor] Adult. Aged. Ankle Brachial Index. Blood Flow Velocity / physiology. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722562.001).
  • [ISSN] 1525-6049
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


98. Malhis M, Al-Bitar S, Farhood S, Zaiat KA: Changes in QT intervals in patients with end-stage renal disease before and after hemodialysis. Saudi J Kidney Dis Transpl; 2010 May;21(3):460-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in QT intervals in patients with end-stage renal disease before and after hemodialysis.
  • To assess the effect of hemodialysis (HD) on QT and corrected QT (QTc) intervals and their dispersions in chronic hemodialyzed patients we studied 85 patients (male/female = 48/37; mean age 44 +/- 17 year) on chronic hemodialysis.
  • Simultaneous 12-lead ECG was recorded before and after HD in a standard setting.
  • ECG parameters, body weight, blood pressure, heart rate, electrolytes (Na+, K+, Ca++, phosphate), urea, and creatinine were measured before and after HD.
  • During HD, the serum potassium and phosphate levels decreased whereas the calcium levels increased.
  • We conclude that QT and QTc interval and dispersion increase in HD patients.
  • [MeSH-minor] Adult. Electrocardiography. Female. Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Arrhythmia.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427869.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


99. Tapiawala S, Vora H, Patel Z, Badve S, Shah B: Subjective global assessment of nutritional status of patients with chronic renal insufficiency and end stage renal disease on dialysis. J Assoc Physicians India; 2006 Dec;54:923-6
MedlinePlus Health Information. consumer health - Malnutrition.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subjective global assessment of nutritional status of patients with chronic renal insufficiency and end stage renal disease on dialysis.
  • There were 27 patients with (CRI) on conservative management, 38 patients with end stage renal disease (ESRD) on maintenance hemodialysis (HD) and 16 patients with ESRD on continuous ambulatory peritoneal dialysis (CAPD).
  • RESULTS: Thirteen (48%) patients with CRI, 22 (58%) patients on HD and 8 (50%) patients on CAPD were malnourished.
  • [MeSH-minor] Adult. Anthropometry. Female. Humans. Kidney Failure, Chronic / therapy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Chronic Kidney Disease.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334008.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] India
  •  go-up   go-down


100. Nasri H, Baradaran A: The influence of serum 25-hydroxy vitamin D levels on Helicobacter Pylori Infections in patients with end-stage renal failure on regular hemodialysis. Saudi J Kidney Dis Transpl; 2007 Jun;18(2):215-9
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of serum 25-hydroxy vitamin D levels on Helicobacter Pylori Infections in patients with end-stage renal failure on regular hemodialysis.
  • This study was designed to determine whether the serum levels of 25-OH vitamin D influence the occurrence of infection with Helicobacter Pylori (H.Pylori) in patients on maintenance hemodialysis (HD).
  • The study subjects were patients with end-stage renal disease who were undergoing maintenance dialysis at the hemodialysis section, Hajar Medical, Educational and Therapeutic Center, Shahrekord, Iran.
  • [MeSH-minor] Adult. Antibodies, Anti-Idiotypic / immunology. Antibodies, Bacterial / immunology. Biomarkers / blood. Cross-Sectional Studies. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Helicobacter pylori / immunology. Humans. Immunoglobulin G / immunology. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496397.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Bacterial; 0 / Biomarkers; 0 / Immunoglobulin G; P6YZ13C99Q / Calcifediol
  •  go-up   go-down






Advertisement